BCRPATIENTBARCODE	DRUGCATEGORY	DRUGDOSAGE	DOSAGEUNITS	NUMBERCYCLES	DAYSTODRUGTREATMENTSTART	DAYSTODRUGTREATMENTEND	INITIALCOURSE	DRUGNAME	REGIMENINDICATION	ROUTEOFADMINISTRATION	
TCGA-01-0628	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0630	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0631	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0633	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0636	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0637	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0639	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-01-0642	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-04-1331	CHEMO	1650	mg	6	36	169	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1331	CHEMO	455	mg	6	36	169	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1331	TARGETED	4.4	mg	null	481	498	null	Velcade	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	7	null	null	null	Gemcitabine	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	7	null	null	null	Doxil	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	3	973	1065	null	Carboplatin	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	3	973	1065	null	Taxotere	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	2	1096	1157	null	Cisplatin	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	2	1096	1157	null	Taxotere	RECURRENCE	null	
TCGA-04-1332	CHEMO	null	null	3	1157	1218	null	Doxil	RECURRENCE	null	
TCGA-04-1332	CHEMO	6	AUC	6	426	608	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1332	CHEMO	175	mg/m2	6	426	608	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1335	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1336	CHEMO	75	mg/m2	6	50	83	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1336	CHEMO	6	AUC	6	50	83	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1336	CHEMO	75	mg/m2	null	179	542	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1337	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1338	CHEMO	null	null	8	0	212	null	Carboplatin	ADJUVANT	null	
TCGA-04-1338	CHEMO	null	null	8	0	212	null	Taxol	ADJUVANT	null	
TCGA-04-1338	CHEMO	812	mg	6	426	510	null	Docetaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1338	CHEMO	800	mg	1	608	638	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1338	CHEMO	10	mg	null	638	null	null	Tamoxifen	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1341	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1342	CHEMO	null	null	6	32	142	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1342	CHEMO	null	null	null	170	478	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1342	CHEMO	null	null	null	170	478	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1342	CHEMO	null	null	null	170	478	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1342	CHEMO	null	null	null	170	478	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1343	CHEMO	175	mg/m2	5	61	180	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1343	CHEMO	5	AUC	5	61	180	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1343	CHEMO	800	mg/m2	5	61	180	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1343	CHEMO	null	null	2	180	272	null	Taxotere	PROGRESSION	null	
TCGA-04-1343	CHEMO	null	null	2	180	272	null	Carboplatin	PROGRESSION	null	
TCGA-04-1343	CHEMO	null	null	4	272	333	null	Topotecan	PROGRESSION	null	
TCGA-04-1343	CHEMO	null	null	4	272	333	null	Navelbine	PROGRESSION	null	
TCGA-04-1343	CHEMO	null	null	null	333	365	null	Topotecan	PROGRESSION	null	
TCGA-04-1346	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1347	CHEMO	1764	mg	6	19	172	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1347	CHEMO	2400	mg	6	19	172	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1347	CHEMO	750	mg	2	19	172	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1347	CHEMO	200	mg	2	19	172	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	8	0	181	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	8	0	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	7	670	850	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	null	881	973	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	9	1003	1155	null	Cisplatin/Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	9	1003	1155	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	3	1215	1246	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1348	CHEMO	null	null	null	1276	1430	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	30	mg/m2	7	436	653	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	75	mg/m2	7	436	653	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	60	mg/m2	1	436	653	null	Cisplatin	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-04-1349	CHEMO	60	mg/m2	1	436	653	null	Paclitaxel	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-04-1349	CHEMO	750	mg/m2	1	436	653	null	Cytoxan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	75	mg/m2	6	1	373	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	175	mg/m2	6	1	373	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1349	CHEMO	135	mg/m2	6	1	373	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1349	TARGETED	5	mg/kg	null	1749	1749	null	Avastin	PROGRESSION	null	
TCGA-04-1350	CHEMO	null	null	null	216	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	CHEMO	null	null	null	216	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	CHEMO	null	null	null	363	null	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	CHEMO	null	null	null	720	null	null	Gemcitibine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	CHEMO	null	null	null	1389	null	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	CHEMO	null	null	null	1389	null	null	Gemcitibine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1350	IMMUNO	null	null	null	1389	null	null	Avastin	PROGRESSION	null	
TCGA-04-1350	TARGETED	null	null	null	1580	null	null	Tamoxifen	PROGRESSION	null	
TCGA-04-1350	TARGETED	null	null	null	1622	null	null	Aromasin	PROGRESSION	null	
TCGA-04-1350	TARGETED	null	null	null	1736	null	null	Fuluestrant	PROGRESSION	null	
TCGA-04-1350	TARGETED	null	null	null	1736	null	null	Faslodex	PROGRESSION	null	
TCGA-04-1351	CHEMO	null	null	null	null	null	null	null	ADJUVANT	null	
TCGA-04-1351	CHEMO	null	null	null	null	null	null	null	RECURRENCE	null	
TCGA-04-1356	CHEMO	1824.5	mg	6	161	312	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1356	CHEMO	4531.3	mg	6	161	312	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1357	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1360	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1361	CHEMO	null	null	6	59	849	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1361	CHEMO	null	null	6	59	849	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1361	CHEMO	null	null	12	59	849	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1361	CHEMO	null	null	1	941	989	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1361	IMMUNO	null	null	null	941	989	null	Avastin	PROGRESSION	null	
TCGA-04-1362	CHEMO	2593	mg	6	7	172	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1362	CHEMO	1689	mg	6	7	172	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1362	CHEMO	13856	mg	6	7	172	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1362	CHEMO	null	null	null	658	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1362	CHEMO	null	null	null	658	null	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1362	CHEMO	null	null	null	658	null	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1364	CHEMO	10500	mg	5	457	579	null	Etoposide	RECURRENCE	null	
TCGA-04-1364	CHEMO	5	AUC	7	31	183	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1364	CHEMO	2408	mg	7	31	183	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1364	CHEMO	235	mg	7	31	183	null	Doxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1364	CHEMO	19.8	mg	2	275	306	null	Topotecan	RECURRENCE	null	
TCGA-04-1364	CHEMO	198	mg	2	275	306	null	Navelbine	RECURRENCE	null	
TCGA-04-1364	CHEMO	1400	mg	2	337	366	null	Hexlalen	RECURRENCE	null	
TCGA-04-1364	CHEMO	6400	mg	2	397	457	null	Gemcitabine	RECURRENCE	null	
TCGA-04-1364	CHEMO	240	mg	2	397	457	null	Cisplatin	RECURRENCE	null	
TCGA-04-1364	CHEMO	7000	mg	14	611	822	null	5F4 Leucovorin	RECURRENCE	null	
TCGA-04-1364	CHEMO	1860	mg	14	611	822	null	Avastin	RECURRENCE	null	
TCGA-04-1364	CHEMO	8.5	mg	1	852	852	null	RBBX 01	RECURRENCE	null	
TCGA-04-1364	CHEMO	260	mg	2	914	944	null	Docetaxel	RECURRENCE	null	
TCGA-04-1364	CHEMO	5	AUC	2	914	944	null	Carboplatin	RECURRENCE	null	
TCGA-04-1365	CHEMO	11760	mg	8	20	188	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1365	CHEMO	6	AUC	8	20	188	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1365	CHEMO	5	AUC	6	2000	null	null	Carbplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1365	CHEMO	5	AUC	4	2063	2195	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1365	CHEMO	4	AUC	2	2063	2195	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1365	CHEMO	null	null	1	null	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1367	CHEMO	1925	mg	7	24	199	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1367	CHEMO	721	mg	7	24	199	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1371	CHEMO	5120	mg	8	7	198	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1371	CHEMO	13200	mg	8	7	198	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1371	CHEMO	1160	mg	8	7	198	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1514	CHEMO	1112	mg	5	31	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1514	CHEMO	617	mg	5	31	123	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-04-1514	CHEMO	494	mg	5	31	123	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-04-1514	CHEMO	5	AUC	3	123	182	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-04-1514	CHEMO	333	mg	3	123	182	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-04-1514	CHEMO	5	AUC	6	1218	1339	null	Carbplatin	RECURRENCE	null	
TCGA-04-1514	CHEMO	665	mg	6	1218	1339	null	Taxotere	RECURRENCE	null	
TCGA-04-1514	CHEMO	51	mg	3	1369	1431	null	Patupilone	RECURRENCE	null	
TCGA-04-1514	CHEMO	201	mg	3	1431	1492	null	Doxil	RECURRENCE	null	
TCGA-04-1514	CHEMO	33.6	mg	4	1522	1584	null	Topotecan	RECURRENCE	null	
TCGA-04-1514	CHEMO	336	mg	4	1522	1584	null	Navelbine	RECURRENCE	null	
TCGA-04-1514	CHEMO	1750	mg	3	1461	1584	null	Avastin	RECURRENCE	null	
TCGA-04-1514	CHEMO	292	mg	3	1612	1673	null	Cisplatin	RECURRENCE	null	
TCGA-04-1514	CHEMO	7792	mg	3	1612	1673	null	Gemcitabine	RECURRENCE	null	
TCGA-04-1517	CHEMO	70	mg/m2	6	35	144	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1517	CHEMO	6	AUC	6	35	144	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1517	CHEMO	null	null	3	352	421	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1517	CHEMO	null	null	3	352	421	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1519	null	null	null	null	null	null	null	null	null	null	
TCGA-04-1525	CHEMO	888	mg	8	16	183	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-04-1525	CHEMO	616	mg	8	16	183	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-04-1525	TARGETED	31	mg	null	436	464	null	Irolfluvin	PROGRESSION	null	
TCGA-04-1530	CHEMO	1218	mg	6	42	152	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1530	CHEMO	678	mg	6	42	152	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1530	CHEMO	1200	mg	6	382	549	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1530	CHEMO	2490	mg	6	382	549	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1536	CHEMO	3360	mg	8	36	231	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1536	CHEMO	2125	mg	8	36	231	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1536	CHEMO	188	mg	8	36	231	null	Doxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1536	CHEMO	null	null	null	517	null	null	Carboplatin	RECURRENCE	null	
TCGA-04-1536	CHEMO	null	null	null	517	null	null	Doxil	RECURRENCE	null	
TCGA-04-1536	CHEMO	null	null	null	517	null	null	Taxotere	RECURRENCE	null	
TCGA-04-1542	CHEMO	2534	mg	8	2	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1542	CHEMO	5	AUC	8	2	182	null	Carbplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1542	CHEMO	17378	mg	8	2	182	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1542	CHEMO	4004	mg	12	1066	1293	null	Paclitaxel	RECURRENCE	null	
TCGA-04-1542	CHEMO	5	AUC	12	1066	1293	null	Carboplatin	RECURRENCE	null	
TCGA-04-1542	CHEMO	122.1	mg	6	1321	1487	null	Paclitaxel	RECURRENCE	null	
TCGA-04-1542	CHEMO	159	mg	2	1501	1529	null	Doxil	RECURRENCE	null	
TCGA-04-1542	CHEMO	32496	mg	11	1564	1796	null	Gemcitabine	RECURRENCE	null	
TCGA-04-1542	CHEMO	11299.9	mg	11	1564	1796	null	Cisplatin	RECURRENCE	null	
TCGA-04-1542	CHEMO	7398	mg	6	2008	2105	null	Avastin	RECURRENCE	null	
TCGA-04-1542	CHEMO	124.15	null	4	2130	2191	null	Docetaxel	RECURRENCE	null	
TCGA-04-1542	CHEMO	4875	mg	4	2130	2191	null	Avastin	RECURRENCE	null	
TCGA-04-1542	CHEMO	5	AUC	3	2222	2283	null	Carboplatin	RECURRENCE	null	
TCGA-04-1542	CHEMO	343	mg	3	2283	2343	null	Doxorubicin	RECURRENCE	null	
TCGA-04-1542	CHEMO	28756	null	9	2343	2527	null	Gemcitabine	RECURRENCE	null	
TCGA-04-1542	CHEMO	2870	mg	9	2343	2527	null	Avastin	RECURRENCE	null	
TCGA-04-1638	CHEMO	968	mg	8	17	192	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1638	CHEMO	2990	mg	8	17	192	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1638	CHEMO	11400	mg	8	17	192	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1638	CHEMO	null	null	null	346	null	null	Doxil	RECURRENCE	null	
TCGA-04-1638	CHEMO	null	null	null	346	null	null	Carboplatin	RECURRENCE	null	
TCGA-04-1638	CHEMO	null	null	null	346	null	null	Taxol	RECURRENCE	null	
TCGA-04-1646	CHEMO	8188	mg	8	18	239	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1646	CHEMO	4709	mg	8	18	239	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1646	CHEMO	1504	mg	8	18	239	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1646	CHEMO	null	null	null	522	null	null	Doxil	OTHER: SPECIFY IN NOTES	null	
TCGA-04-1646	CHEMO	null	null	null	522	null	null	Topotecan	OTHER: SPECIFY IN NOTES	null	
TCGA-04-1648	CHEMO	23296	mg	8	3	149	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1648	CHEMO	5140	mg	8	3	149	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1648	CHEMO	2544	mg	8	3	149	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1648	CHEMO	40	mg	null	247	null	null	Doxil	RECURRENCE	null	
TCGA-04-1648	CHEMO	null	null	null	247	null	null	Topotecan	RECURRENCE	null	
TCGA-04-1648	CHEMO	129	mg	null	247	null	null	Taxotere	RECURRENCE	null	
TCGA-04-1648	IMMUNO	null	null	null	247	null	null	Avastin	RECURRENCE	null	
TCGA-04-1649	CHEMO	null	null	null	1704	null	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1649	CHEMO	null	null	null	1704	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1651	CHEMO	4416	mg	6	24	150	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1651	CHEMO	3228	mg	6	24	150	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1651	CHEMO	1869	mg	6	24	150	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1651	CHEMO	null	null	null	638	null	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1651	CHEMO	null	null	null	994	null	null	Gemcitibine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-04-1652	CHEMO	5	AUC	8	62	199	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1652	CHEMO	175	mg/m2	8	62	199	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1652	CHEMO	800	mg/m2	8	62	199	null	Gemicitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1652	CHEMO	30	mg/m2	4	894	955	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1654	CHEMO	null	null	null	877	null	null	Carboplatin	PROGRESSION	null	
TCGA-04-1654	CHEMO	280	mg	2	31	52	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-04-1654	CHEMO	380	mg	2	31	52	null	Taxol	ADJUVANT	IV AND IP	
TCGA-04-1654	CHEMO	null	null	null	877	null	null	Taxol	PROGRESSION	null	
TCGA-04-1655	CHEMO	1288	mg	6	34	138	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-04-1655	CHEMO	953	mg	6	34	138	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-04-1655	CHEMO	574	mg	6	34	138	null	Taxol	ADJUVANT	IV AND IP	
TCGA-04-1655	CHEMO	null	null	null	183	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-04-1655	CHEMO	null	null	null	839	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-0364	CHEMO	null	null	6	31	188	null	Carboplatinum	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0364	CHEMO	125	mg/m2	6	31	188	null	taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0365	CHEMO	273	mg	3	46	70	null	carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0365	CHEMO	175	mg/m2	3	15	70	null	taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0366	CHEMO	null	null	6	5	113	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0366	CHEMO	135	mg/m2	6	5	113	null	taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0366	CHEMO	1.5	mg/m2	4	224	274	null	topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-0367	CHEMO	null	null	5	9	92	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0367	CHEMO	175	mg/m2	5	9	92	null	taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0367	CHEMO	1145	mg	4	150	null	null	gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	null	null	4	8	74	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	175	mg/m2	4	8	74	null	taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	80	mg	1	78	78	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	null	null	1	99	99	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	1000	mg/m2	1	99	99	null	gemcitabin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	40	mg/m2	1	297	297	null	doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-0369	CHEMO	null	null	null	309	null	null	topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1659	CHEMO	75	mg/m2	6	16	136	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1659	CHEMO	75	mg/m2	6	16	136	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1659	CHEMO	null	null	6	16	136	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1659	CHEMO	110	mg/m2	6	37	136	null	Taxp;	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1659	CHEMO	50	mg/m2	1	180	180	null	Hexamethylmelamine	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-09-1661	CHEMO	40	mg/m2	4	213	332	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	192	mg	6	58	165	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	135	mg	6	58	165	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	6	null	4	641	709	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	800	mg/m2	1	758	766	null	Gemcitabine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	70	mg/m2	17	828	940	null	Taxol	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1661	CHEMO	30	mg/m2	5	1017	1052	null	Taxotere	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1661	HORMONAL	20	mg	null	498	641	null	Tamoxifen	OTHER: SPECIFY IN NOTES	null	
TCGA-09-1662	CHEMO	75	mg/m2	6	32	141	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	6	null	1	15	15	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	175	mg/m2	1	15	15	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	600	mg/m2	6	32	141	null	Gemzar	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	5	null	6	1128	1233	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	60	mg/m2	6	1128	1233	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	5	null	9	1590	1732	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	60	mg/m2	9	1590	1732	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	390	mg	2	1947	1968	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	98	mg/m2	2	1947	1968	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	100	mg	6	1989	2052	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	40	mg/m2	12	2073	2405	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	2	mg/m2	9	2426	2650	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	3	mg/m2	9	2457	2461	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	4	mg/m2	9	2482	2602	null	Toptecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	2	mg/m2	9	2608	2623	null	Toptecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	4	mg/m2	9	2623	2650	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	null	null	2	2530	2537	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	47	mg	3	2684	2697	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	CHEMO	954	mg	3	2684	2697	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1662	HORMONAL	1	mg	null	1926	null	null	Armidex	RECURRENCE	null	
TCGA-09-1662	TARGETED	10	mg/kg	null	2503	2517	null	Avastin	PROGRESSION	null	
TCGA-09-1662	TARGETED	10	mg/kg	null	2566	2650	null	Avastin	PROGRESSION	null	
TCGA-09-1664	CHEMO	70	null	6	14	138	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1664	CHEMO	6	null	6	14	138	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1665	CHEMO	175	mg/m2	6	33	211	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1665	CHEMO	6	null	6	33	211	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1665	CHEMO	6	null	6	916	1021	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1665	HORMONAL	null	null	null	400	487	null	Tamoxifen	RECURRENCE	null	
TCGA-09-1666	CHEMO	6	null	5	101	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	6	null	3	-3	73	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	135	mg/m2	3	27	73	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	60	mg/m2	5	101	181	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	6	null	5	615	708	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	1000	mg/m2	5	615	708	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1666	CHEMO	null	null	null	null	null	null	Carboplatin	PROGRESSION	null	
TCGA-09-1666	CHEMO	null	null	null	null	null	null	Taxotere	PROGRESSION	null	
TCGA-09-1666	CHEMO	null	null	null	1507	1597	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1666	HORMONAL	null	null	null	1612	1765	null	Femara	PROGRESSION	null	
TCGA-09-1666	IMMUNO	2	mg	null	255	480	null	Oca Rex Oregovomab	ADJUVANT	null	
TCGA-09-1667	CHEMO	6	null	6	7	118	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1667	CHEMO	175	mg/m2	6	7	118	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1667	CHEMO	6	null	5	559	685	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-09-1667	CHEMO	40	mg/m2	20	820	1875	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1667	CHEMO	6	null	1	1126	1126	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-1668	CHEMO	60	mg/m2	9	151	320	null	Taxotere	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1668	CHEMO	480	mg	6	31	135	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1668	CHEMO	120	mg	6	31	135	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1669	CHEMO	175	mg/m2	6	27	131	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1669	CHEMO	6	null	6	27	131	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1670	CHEMO	null	null	null	null	null	null	Taxol	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-09-1670	CHEMO	6	null	6	74	179	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1670	CHEMO	175	mg/m2	6	74	179	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1672	CHEMO	null	null	null	30	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1672	CHEMO	null	null	null	30	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1673	CHEMO	null	null	null	31	null	null	Taxol or Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1673	CHEMO	null	null	null	31	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1674	CHEMO	175	mg/m2	6	41	145	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1674	CHEMO	6	null	6	41	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1675	CHEMO	190	mg	null	75	187	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1675	CHEMO	190	mg	3	54	68	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1675	CHEMO	60	mg/m2	3	54	68	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-1675	CHEMO	80	mg/m2	null	75	187	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2053	CHEMO	6	AUC	6	34	138	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2053	CHEMO	175	mg/m2	6	34	138	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2054	CHEMO	6	AUC	6	37	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2054	CHEMO	175	mg/m2	6	37	160	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2054	CHEMO	50	mg/m2	3	243	299	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-2054	CHEMO	null	null	3	335	427	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-2054	CHEMO	null	null	3	428	512	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-09-2056	CHEMO	null	null	6	31	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-09-2056	CHEMO	null	null	6	31	153	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0925	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-10-0926	CHEMO	860	mg/m2	6	8	143	null	Taxol	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0926	CHEMO	4500	mg/m2	6	8	143	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0926	CHEMO	975	mg/m2	13	290	729	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0926	IMMUNO	22,920	mg/m2	null	232	null	null	ILIZ	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	1800	mg/m2	6	9	121	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	2940	mg/m2	6	9	121	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	5400	mg/m2	10	1017	1301	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	60	mg/m2	10	1601	1686	null	Arimidex	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	2320	mg/m2	10	1686	1910	null	Taxol	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	845	mg/m2	10	1938	2302	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	CHEMO	9920	mg/m2	10	2330	2463	null	Gemcitabine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0927	HORMONAL	12000	mg/m2	null	1336	1640	null	Tamoxifen	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0928	null	null	null	null	null	null	null	null	null	null	
TCGA-10-0930	CHEMO	1800	mg/m2	6	8	124	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0930	CHEMO	2520	mg/m2	6	8	124	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0930	CHEMO	810	mg/m2	3	694	736	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0930	CHEMO	250	mg/m2	3	694	736	null	Carbo	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0930	CHEMO	210	mg/m2	3	782	838	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0930	HORMONAL	2400	mg/m2	null	1238	1311	null	Tamoxifen	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	2430	mg/m2	6	19	124	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	null	null	6	19	124	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	2268	mg/m2	6	19	124	null	Herceptin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	1632	mg/m2	6	386	509	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	3240	mg/m2	6	386	509	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	1840	mg/m2	8	538	666	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	440	mg/m2	4	538	666	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	420	mg	6	538	666	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	23.78	mg/m2	3	792	848	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	CHEMO	231	mg/m2	3	876	566	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	HORMONAL	1880	mg/m2	null	335	383	null	Tamoxifen	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0931	TARGETED	14000	mg/m2	null	792	848	null	Irressa	RECURRENCE	INTRAVENOUS (IV)	
TCGA-10-0933	CHEMO	1740	mg/m2	6	20	132	null	Taxol	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0933	CHEMO	2160	mg/m2	6	20	132	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0934	CHEMO	525	mg/m2	3	31	55	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0934	CHEMO	null	null	3	31	55	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0935	CHEMO	240	mg/m2	1	34	34	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0935	CHEMO	385	mg/m2	1	34	34	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	1615	mg/m2	null	20	62	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	1800	mg/m2	null	89	194	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	2280	mg/m2	null	89	194	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	1035	mg/m2	3	621	678	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	225	mg/m2	3	678	800	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	750	mg/m2	6	810	936	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-10-0936	CHEMO	11200	mg/m2	3	939	1007	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-10-0936	HORMONAL	2.5	mg/day	null	237	615	null	Letrozole	PROGRESSION	INTRAVENOUS (IV)	
TCGA-10-0937	CHEMO	1980	mg/m2	6	33	146	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0937	CHEMO	3990	mg/m2	6	33	146	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0937	CHEMO	140	mg/m2	6	244	296	null	Doxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0937	CHEMO	21	mg/m2	1	346	null	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0937	CHEMO	4176	mg/m2	3	null	451	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-10-0938	CHEMO	3150	mg/m2	6	41	188	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0938	CHEMO	960	mg/m2	6	41	188	null	Taxotere	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0938	HORMONAL	225	mg/m2	null	30	148	null	Letrozole	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-10-0938	HORMONAL	3.75	mg/m2	null	30	153	null	Lupron	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-13-0714	CHEMO	5	null	4	12	null	null	Carboplatin	ADJUVANT	ORAL	
TCGA-13-0714	CHEMO	175	mg/m2	4	12	null	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0714	CHEMO	null	null	4	12	null	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0717	CHEMO	5	null	8	9	182	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0717	CHEMO	175	mg/m2	8	9	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0720	CHEMO	5	null	8	7	180	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0720	CHEMO	175	mg/m2	8	7	180	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0720	CHEMO	560	mg/m2	7	239	292	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0723	CHEMO	null	null	8	28	200	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0723	CHEMO	175	mg/m2	8	28	200	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0724	CHEMO	null	null	1	75	75	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0725	CHEMO	null	null	6	15	131	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0725	CHEMO	175	mg/m2	6	15	131	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0725	CHEMO	75	mg/m2	2	190	215	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0726	CHEMO	null	null	7	29	168	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0726	CHEMO	175	mg/m2	7	29	168	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0727	CHEMO	null	null	6	9	120	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0727	CHEMO	175	mg/m2	6	9	120	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0727	HORMONAL	2.5	mg	null	230	267	null	Femara	ADJUVANT	null	
TCGA-13-0730	null	null	null	null	null	null	null	null	null	null	
TCGA-13-0751	CHEMO	null	null	6	7	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0751	CHEMO	175	mg/m2	6	7	126	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0751	CHEMO	75	mg/m2	4	195	266	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0751	CHEMO	500	mg/m2	2	195	266	null	Gemcitabine	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0755	CHEMO	230	mg/m2	2	19	41	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0757	CHEMO	135	mg/m2	6	36	152	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0757	CHEMO	null	null	6	36	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0757	CHEMO	null	mg/m2	3	210	266	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0758	CHEMO	6	null	8	14	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0758	CHEMO	175	mg/m2	8	14	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0760	CHEMO	5	null	8	-1275	-1098	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0760	CHEMO	175	mg/m2	8	-1275	-1098	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0761	CHEMO	5	null	8	52	220	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0761	CHEMO	75	mg/m2	8	52	220	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0762	CHEMO	75	mg/m2	6	28	141	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0762	CHEMO	135	mg/m2	6	28	141	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0762	CHEMO	60	mg/m2	6	28	141	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0764	CHEMO	6	null	6	55	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0764	CHEMO	175	mg/m2	6	55	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0764	TARGETED	15	mg/kg	null	76	160	null	Bevacizumab	ADJUVANT	null	
TCGA-13-0765	CHEMO	75	mg/m2	6	50	163	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0765	CHEMO	135	mg/m2	6	50	163	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0765	CHEMO	60	mg/m2	6	50	163	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0765	HORMONAL	20	mg	null	589	654	null	Tamoxifen	ADJUVANT	null	
TCGA-13-0765	TARGETED	15	mg/m2	null	71	155	null	Bevacizumab	ADJUVANT	null	
TCGA-13-0765	TARGETED	15	mg/kg	null	176	519	null	Bevacizumab	ADJUVANT	null	
TCGA-13-0766	CHEMO	null	null	2	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0766	CHEMO	null	mg/m2	4	null	182	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0766	CHEMO	100	mg/m2	4	null	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0768	CHEMO	6	null	2	36	56	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0768	CHEMO	175	mg/m2	2	36	56	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0768	CHEMO	75	mg/m2	4	77	147	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0768	CHEMO	135	mg/m2	4	77	147	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0768	CHEMO	60	mg/m2	4	77	147	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0791	CHEMO	null	null	6	36	141	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0791	CHEMO	175	mg/m2	6	36	141	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0791	CHEMO	135	mg/m2	4	213	281	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0792	CHEMO	75	mg/m2	6	34	160	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0792	CHEMO	135	mg/m2	6	34	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0792	CHEMO	60	mg/m2	6	34	160	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0793	CHEMO	null	null	6	47	159	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0793	CHEMO	175	mg/m2	6	47	159	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0793	IMMUNO	2	mg	null	200	362	null	Abagovomab or Placebo	ADJUVANT	null	
TCGA-13-0794	CHEMO	null	null	6	26	132	null	Carboplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0794	CHEMO	60	mg/m2	6	26	132	null	Docetaxel	ADJUVANT	IV AND IP	
TCGA-13-0795	CHEMO	6	null	6	100	204	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0795	CHEMO	175	mg/m2	6	100	204	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0797	CHEMO	599	mg	6	41	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0797	CHEMO	135	mg/m2	6	41	145	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0799	CHEMO	75	mg/m2	6	36	146	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0799	CHEMO	135	mg/m2	6	36	146	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0799	CHEMO	60	mg/m2	6	36	146	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0800	CHEMO	null	mg/m2	6	30	142	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0800	CHEMO	null	mg/m2	6	30	142	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0800	CHEMO	null	mg/m2	6	30	142	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0801	CHEMO	null	mg/m2	6	32	144	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0801	CHEMO	null	mg/m2	6	32	144	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0801	CHEMO	null	mg/m2	6	32	144	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0802	CHEMO	null	null	6	62	188	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0802	CHEMO	null	mg/m2	6	62	188	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0803	CHEMO	null	null	6	114	225	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0803	CHEMO	1050	mg/m2	6	114	225	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0804	CHEMO	null	null	6	26	161	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0804	CHEMO	null	mg/m2	6	26	161	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0804	TARGETED	null	null	null	270	270	null	90Y-HU3S193	ADJUVANT	null	
TCGA-13-0805	CHEMO	null	null	6	17	150	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0805	CHEMO	null	mg/m2	6	17	150	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0807	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-13-0807	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-13-0807	CHEMO	null	null	null	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0807	CHEMO	null	null	null	null	null	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0883	CHEMO	6	null	6	31	142	null	Carbobplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0883	CHEMO	175	mg/m2	6	31	142	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0883	CHEMO	75	mg/m2	6	226	350	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0884	CHEMO	5	null	6	55	191	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0884	CHEMO	60	mg/m2	6	55	191	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0884	CHEMO	800	mg/m2	6	55	191	null	Gemicitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0884	CHEMO	133	mg/m2	4	240	307	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-0884	CHEMO	74	mg/m2	4	240	307	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-0885	CHEMO	null	null	6	6	110	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0885	CHEMO	1050	mg/m2	6	6	110	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0885	CHEMO	null	null	3	null	208	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0886	CHEMO	null	null	6	12	132	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0886	CHEMO	null	mg/m2	6	12	132	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0886	CHEMO	null	mg/m2	3	221	263	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0887	CHEMO	null	null	6	7	114	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0887	CHEMO	null	mg/m2	6	-3	114	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0887	CHEMO	null	mg/m2	4	183	267	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0888	CHEMO	null	null	8	54	231	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0888	CHEMO	null	mg/m2	8	54	231	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0888	HORMONAL	null	mg	null	252	null	null	Femara	ADJUVANT	null	
TCGA-13-0889	CHEMO	null	null	6	53	158	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0889	CHEMO	null	mg/m2	6	53	158	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0890	CHEMO	null	null	8	14	235	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0890	CHEMO	null	mg/m2	8	14	235	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0891	CHEMO	null	null	6	70	182	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0891	CHEMO	1050	mg/m2	6	70	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0893	CHEMO	5	null	8	80	284	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0893	CHEMO	175	mg/m2	8	80	284	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0893	HORMONAL	2.5	mg/m2	null	340	566	null	Femara	ADJUVANT	null	
TCGA-13-0894	CHEMO	5	null	8	47	216	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0894	CHEMO	175	mg/m2	8	47	216	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0894	CHEMO	600	mg/m2	2	307	330	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0897	CHEMO	null	null	6	34	139	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0897	CHEMO	1050	mg/m2	6	34	139	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0899	CHEMO	null	null	6	16	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0899	CHEMO	1050	mg/m2	6	16	126	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0900	CHEMO	5	null	6	38	162	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0900	CHEMO	null	null	6	38	162	null	Paciltaxal	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0901	CHEMO	6	null	6	44	165	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0901	CHEMO	175	mg/m2	6	44	165	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0901	TARGETED	250	mg/m2	null	44	88	null	Cetuximab	ADJUVANT	null	
TCGA-13-0903	CHEMO	null	null	6	22	127	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0903	CHEMO	1050	mg/m2	6	22	127	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0903	TARGETED	null	mg/m2	null	22	140	null	Cetuximab	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0903	TARGETED	null	mg/m2	null	168	334	null	Cetuximab	ADJUVANT	null	
TCGA-13-0904	CHEMO	null	null	2	63	84	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0904	CHEMO	175	mg/m2	2	63	84	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0904	CHEMO	null	null	6	105	250	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0904	CHEMO	null	mg/m2	6	105	250	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0905	CHEMO	6	null	6	20	124	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0905	CHEMO	175	mg/m2	6	20	124	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0905	CHEMO	500	mg/m2	4	152	222	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0906	CHEMO	75	mg/m2	6	34	146	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0906	CHEMO	135	mg/m2	6	34	146	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0906	CHEMO	60	mg/m2	6	34	146	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0908	CHEMO	6	null	6	24	135	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0908	CHEMO	175	mg/m2	6	24	135	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0908	CHEMO	70	mg/m2	3	198	244	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0910	CHEMO	null	null	6	70	174	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0910	CHEMO	175	mg/m2	6	70	174	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0910	CHEMO	60	mg/m2	3	237	288	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0911	CHEMO	null	null	7	49	188	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0911	CHEMO	175	mg/m2	7	49	188	null	paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0912	CHEMO	75	mg/m2	6	35	146	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0912	CHEMO	135	mg/m2	6	35	146	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0912	CHEMO	60	mg/m2	6	35	146	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0913	CHEMO	75	mg/m2	6	35	161	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0913	CHEMO	135	mg/m2	6	35	161	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0913	CHEMO	60	mg/m2	6	35	161	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0916	CHEMO	75	mg/m2	6	35	160	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0916	CHEMO	135	mg/m2	6	35	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0916	CHEMO	60	mg/m2	6	35	160	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0916	TARGETED	15	mg/m2	null	70	181	null	Bevacizumab	ADJUVANT	null	
TCGA-13-0919	CHEMO	null	null	6	42	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0919	CHEMO	175	mg/m2	6	42	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0920	CHEMO	null	null	null	null	151	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0921	CHEMO	null	null	6	35	140	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-0921	CHEMO	null	null	6	35	140	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-13-0923	CHEMO	75	mg/m2	6	39	151	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0923	CHEMO	135	mg/m2	6	39	151	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0923	CHEMO	60	mg/m2	6	39	151	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-0924	CHEMO	null	null	6	38	143	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0924	CHEMO	175	mg/m2	6	38	143	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-0924	TARGETED	920	mg	null	60	143	null	Bevacizumab or Placebo	ADJUVANT	null	
TCGA-13-0924	TARGETED	15	mg/kg	null	164	213	null	Bevacizumab or placebo	ADJUVANT	null	
TCGA-13-1403	CHEMO	75	mg/m2	6	27	141	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1403	CHEMO	135	mg/m2	6	27	141	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1403	CHEMO	60	mg/m2	6	27	141	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1404	CHEMO	6	null	6	50	156	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1404	CHEMO	75	mg/m2	3	232	274	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1404	CHEMO	175	mg/m2	6	50	156	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1405	CHEMO	599	mg	7	23	147	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1405	CHEMO	175	mg/m2	7	23	147	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1407	CHEMO	5	null	7	42	184	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1407	CHEMO	175	mg/m2	7	42	184	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1408	CHEMO	175	mg/m2	5	8	91	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1408	CHEMO	75	mg/m2	2	152	null	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1408	CHEMO	135	mg/m2	2	152	null	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1408	CHEMO	60	mg/m2	2	152	null	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1408	CHEMO	5	null	5	8	91	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1409	CHEMO	5	null	6	94	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1409	CHEMO	175	mg/m2	6	94	null	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1410	CHEMO	5	null	3	39	83	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1410	CHEMO	175	mg/m2	3	39	83	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1410	CHEMO	75	mg/m2	2	103	125	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1410	CHEMO	135	mg/m2	2	103	125	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1411	CHEMO	5	null	6	8	128	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1411	CHEMO	175	mg/m2	6	8	128	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1412	CHEMO	5	null	5	37	121	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1412	CHEMO	175	mg/m2	5	37	121	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1412	CHEMO	75	mg/m2	2	156	null	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1412	CHEMO	135	mg/m2	2	156	null	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1412	CHEMO	60	mg/m2	2	156	null	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-13-1477	CHEMO	175	mg/m2	7	56	205	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1477	CHEMO	360	mg/m2	7	56	205	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1481	CHEMO	175	mg/m2	6	11	131	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1481	CHEMO	5	null	6	11	131	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1481	CHEMO	null	null	3	198	242	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1482	CHEMO	5	null	6	33	152	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1482	CHEMO	175	mg/m2	6	33	152	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1483	CHEMO	75	mg/m2	2	218	238	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1483	CHEMO	5	null	6	35	175	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1483	CHEMO	174	mg/m2	6	35	175	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1484	CHEMO	null	null	6	86	190	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1484	CHEMO	null	null	6	86	190	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1485	CHEMO	5	null	6	45	149	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1485	CHEMO	175	mg/m2	6	45	149	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1487	CHEMO	300	mg/m2	6	17	128	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1487	CHEMO	75	mg/m2	6	17	128	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1487	CHEMO	75	mg/m2	1	207	207	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1487	CHEMO	135	mg/m2	6	256	412	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1488	CHEMO	5	null	8	8	164	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1488	CHEMO	175	mg/m2	8	8	164	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1489	CHEMO	75	mg/m2	1	272	272	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1489	CHEMO	6	null	7	41	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1489	CHEMO	175	mg/m2	7	41	181	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1491	CHEMO	4	null	6	42	154	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1491	CHEMO	175	mg/m2	6	42	154	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1491	CHEMO	135	mg/m2	6	245	401	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1492	CHEMO	5	null	7	48	247	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1492	CHEMO	175	mg/m2	7	48	247	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1494	CHEMO	null	null	6	null	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1494	CHEMO	null	null	6	null	181	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1495	CHEMO	6	null	6	21	139	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1495	CHEMO	175	mg/m2	6	21	139	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1495	CHEMO	175	mg/m2	12	230	547	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1495	TARGETED	250	mg/m2	null	21	118	null	Cetuximab	ADJUVANT	null	
TCGA-13-1495	TARGETED	250	mg/m2	null	146	223	null	Cetuximab	ADJUVANT	null	
TCGA-13-1496	CHEMO	6	null	1	33	33	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1496	CHEMO	175	mg/m2	1	33	33	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1497	CHEMO	6	null	6	22	127	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1497	CHEMO	175	mg/m2	6	22	127	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1497	CHEMO	75	mg/m2	1	185	185	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1497	TARGETED	250	mg/m2	null	22	71	null	Cetuximab	ADJUVANT	null	
TCGA-13-1498	CHEMO	5	null	10	7	215	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1498	CHEMO	175	mg/m2	10	7	215	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1498	HORMONAL	2.5	mg	null	249	631	null	Femara	ADJUVANT	null	
TCGA-13-1499	CHEMO	6	null	2	76	96	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1499	CHEMO	135	mg/m2	2	76	96	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1499	CHEMO	75	mg/m2	4	117	186	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1499	CHEMO	135	mg/m2	4	117	186	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1499	CHEMO	60	mg/m2	4	117	186	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1500	CHEMO	null	null	6	null	136	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1500	CHEMO	null	null	6	null	136	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1500	CHEMO	40	mg/m2	2	197	225	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-13-1501	CHEMO	5	null	6	78	183	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1501	CHEMO	175	mg/m2	6	78	183	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1504	CHEMO	null	null	null	null	283	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1504	CHEMO	null	null	null	null	283	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1505	CHEMO	null	null	5	27	null	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1505	CHEMO	null	null	5	27	null	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-13-1505	CHEMO	null	null	5	27	null	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-13-1506	CHEMO	75	mg/m2	1	50	51	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1506	CHEMO	65	mg/m2	1	50	51	null	Docetaxel	ADJUVANT	IV AND IP	
TCGA-13-1506	CHEMO	75	mg/m2	1	79	80	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1506	CHEMO	800	mg/m2	1	79	80	null	Gemcitabine	ADJUVANT	IV AND IP	
TCGA-13-1506	CHEMO	4	null	3	99	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1506	CHEMO	800	mg/m2	3	99	null	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1507	CHEMO	37.5	mg/m2	5	54	null	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-13-1507	CHEMO	135	mg/m2	5	54	null	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-13-1507	CHEMO	60	mg/m2	5	54	null	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-13-1509	CHEMO	5	null	6	21	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1509	CHEMO	175	mg/m2	6	21	126	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1510	CHEMO	null	null	null	null	null	null	null	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1511	CHEMO	5	null	2	21	46	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1511	CHEMO	600	mg	3	67	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1511	CHEMO	800	mg/m2	3	67	null	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1512	CHEMO	700	mg	2	73	94	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-13-1512	CHEMO	175	mg/m2	2	73	94	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0987	CHEMO	null	null	6	91	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0987	CHEMO	null	null	6	91	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0987	CHEMO	null	null	3	427	442	null	Topotecan	RECURRENCE	null	
TCGA-20-0990	CHEMO	480	mg	6	116	235	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0990	CHEMO	175	mg/m2	6	116	235	null	Paclitaxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0990	CHEMO	1240	mg	5	900	998	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-20-0990	CHEMO	320	mg	6	1033	1174	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-20-0990	CHEMO	47	mg	6	1033	1174	null	Liposomal Doxorubican	RECURRENCE	INTRAVENOUS (IV)	
TCGA-20-0991	CHEMO	425	mg/m2	3	71	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0996	CHEMO	null	null	3	167	223	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0996	CHEMO	175	mg/m2	3	167	223	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-0996	CHEMO	4	mg/m2	15	443	589	null	Topotecan	ADJUVANT	null	
TCGA-20-0996	CHEMO	40	mg/m2	13	615	1077	null	Liposomal Doxorubicin	ADJUVANT	ORAL	
TCGA-20-0996	CHEMO	50	mg	6	1106	null	null	Etoposide	ADJUVANT	ORAL	
TCGA-20-1682	CHEMO	175	mg/m2	6	40	144	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1682	CHEMO	6	null	6	40	144	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1683	CHEMO	6	null	6	17	135	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1683	CHEMO	175	mg/m2	6	17	135	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1683	HORMONAL	20	mg	null	618	null	null	Tamoxifen	ADJUVANT	null	
TCGA-20-1684	CHEMO	6	null	4	42	119	null	Carboplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-20-1684	CHEMO	60	mg/m2	4	42	119	null	Taxol	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-20-1684	CHEMO	15	mg/kg	4	42	119	null	Bevacizumab	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-20-1685	CHEMO	15	mg/kg	6	38	143	null	Bevacizumab	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1685	CHEMO	6	null	6	38	143	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1685	CHEMO	175	mg/m2	6	38	143	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1686	CHEMO	175	mg/m2	6	26	131	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1686	CHEMO	5	null	6	26	131	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1687	CHEMO	null	null	6	42	172	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-20-1687	CHEMO	null	null	6	42	172	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	2880	mg	6	14	119	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	2100	mg	6	14	119	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	6061	mg	5	526	328	null	Gemcitabine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	60	mg	6	null	null	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	2540	mg	5	1226	1331	null	Paclitaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	50	mg	2	1352	1380	null	Vinorelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1021	CHEMO	25	mg	1	-418	-418	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	2730	mg	7	29	161	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	2170	mg	7	29	161	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	17200	mg	12	613	741	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	820	mg	12	613	741	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	27.5	mg	5	762	817	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	640	mg	10	852	936	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	2500	mg	7	1056	886	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	8120	mg	5	1273	1356	null	Cyclophosphamide	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1022	CHEMO	1560	mg	1	1377	1377	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1023	CHEMO	120	mg	2	1427	1455	null	Cisplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1023	CHEMO	198	mg	2	1582	1603	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1023	CHEMO	300	mg	4	1272	1364	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1023	CHEMO	1100	mg	2	1386	1407	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1024	CHEMO	2556	mg	12	224	529	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1024	CHEMO	1608	mg	6	13	304	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1024	CHEMO	776	mg	6	13	304	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1024	CHEMO	541	mg	6	13	304	null	Carboplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1026	CHEMO	3420	mg	6	7	108	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1026	CHEMO	1560	mg	6	7	108	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1026	CHEMO	5648	mg	5	866	936	null	Gemcitabine	RECURRENCE	IV AND IP	
TCGA-23-1026	CHEMO	520	mg	5	866	936	null	Cisplatin	RECURRENCE	IV AND IP	
TCGA-23-1027	CHEMO	2088	mg	5	26	129	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1027	CHEMO	1281	mg	5	26	129	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1027	CHEMO	748	mg	5	165	249	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1027	CHEMO	360	mg	5	165	249	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1027	CHEMO	10932	mg	5	769	866	null	Gemcitabine	PROGRESSION	IV AND IP	
TCGA-23-1027	CHEMO	450	mg	5	769	866	null	Paclitaxel	PROGRESSION	IV AND IP	
TCGA-23-1028	CHEMO	1600	mg	4	26	110	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	2900	mg	4	26	110	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	201	mg	3	173	229	null	Doxorubicin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	2802	mg	6	749	859	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	846	mg	6	749	859	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	40.89	mg	11	908	1006	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	417.5	mg	8	1112	969	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	10.3	mg	3	1140	1153	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	2667	mg	5	1363	1461	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	1552	mg	1	1461	1461	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	525	mg	1	1461	1461	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	3100	mg	2	1468	1489	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1028	CHEMO	100	mg	2	1468	1489	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1029	CHEMO	375	mg	3	30	78	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-23-1029	CHEMO	1212	mg	3	30	78	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-23-1030	CHEMO	540	mg	6	622	766	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1030	CHEMO	5010	mg	6	61	164	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1030	CHEMO	2130	mg	6	61	164	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1030	CHEMO	2160	mg	8	242	72	null	Xyotax	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	null	null	7	25	165	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	2305	mg	7	25	165	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	225	mg	3	265	321	null	Doxorubicin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	16500	mg	11	341	445	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	715	mg	11	341	445	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	280	mg	2	459	484	null	Docetaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1031	CHEMO	1000	mg	2	459	476	null	Xeloda	PROGRESSION	ORAL	
TCGA-23-1031	CHEMO	11.4	mg	2	540	554	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1032	null	null	null	null	null	null	null	null	null	null	
TCGA-23-1107	null	null	null	null	null	null	null	null	null	null	
TCGA-23-1109	null	null	null	null	null	null	null	null	null	null	
TCGA-23-1110	CHEMO	16800	mg	4	333	375	null	Xeloda	RECURRENCE	ORAL	
TCGA-23-1110	CHEMO	1800	mg	6	6	110	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1110	CHEMO	3960	mg	6	6	110	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1110	CHEMO	6	mg	3	179	235	null	Ovarex/IND	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1111	CHEMO	5850	mg	5	45	129	null	Investigal drug Avastin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1111	CHEMO	3389	mg	6	24	129	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1111	CHEMO	1860	mg	6	24	129	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	1650	mg	3	27	74	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	870	mg	3	27	74	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	11282	mg	4	102	187	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	528	mg	4	102	187	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	816	mg	12	225	253	null	Doxoribicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1113	CHEMO	910	mg	9	253	873	null	Docetaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	null	mg	6	43	182	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	null	mg	6	43	182	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	520	mg	4	1159	1222	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	5500	mg	2	1324	1350	null	Gemzar	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	260	mg	2	1324	1350	null	Cisplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	1190	mg	3	1357	1425	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	9625	mg	3	1348	1425	null	Gemzar	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	475	mg	7	1741	1918	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	20.4	mg	6	1985	2026	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	1400	mg	5	663	747	null	Paclitaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	2100	mg	5	663	747	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1114	CHEMO	1305	mg	3	865	907	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1116	CHEMO	2100	mg	6	19	187	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-23-1116	CHEMO	1746	mg	6	19	187	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-23-1116	CHEMO	1530	mg	6	306	418	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1116	CHEMO	11028	mg	6	306	418	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	6470	mg	11	22	294	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	92	mg	8	459	624	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	3450	mg	3	712	757	null	Cyclophosphamide	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	600	mg	5	781	863	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	280	mg	5	890	928	null	Docetaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1117	CHEMO	3960	mg	4	951	993	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1118	CHEMO	300	mg	6	56	196	null	Carboplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1119	CHEMO	2230	mg	6	3389	3129	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1119	CHEMO	2700	mg	6	18	125	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1120	CHEMO	700	mg	5	63	146	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1120	CHEMO	2090	mg	5	63	146	null	Paclitaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-23-1121	CHEMO	3135	mg	6	31	194	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1121	CHEMO	1362	mg	6	31	194	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1121	CHEMO	2400	mg	4	53	152	null	Avastin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	4200	mg	8	27	244	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	15900	mg	20	501	686	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	3500	mg	5	707	754	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	5900	mg	9	775	859	null	Gemcitabine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	72	mg	6	921	1031	null	Ifosfamide	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1122	CHEMO	240	mg	6	1054	1089	null	Cisplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-1123	CHEMO	4800	mg	8	7	-115	null	Carboplatin	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-23-1123	CHEMO	2000	mg	8	7	-115	null	Paclitaxel	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-23-1123	CHEMO	456	mg	6	452	599	null	Doxorubicin	OTHER: SPECIFY IN NOTES	null	
TCGA-23-1123	CHEMO	39.9	mg	3	812	894	null	Topotecan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-23-1124	CHEMO	4950	mg	9	19	197	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1124	CHEMO	18000	mg	18	676	872	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1124	CHEMO	3080	mg	11	1070	1286	null	Paclitaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1124	CHEMO	180	mg	6	1307	1342	null	Vinorelbine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-1124	CHEMO	390	mg	6	1363	1510	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1124	CHEMO	12	mg	4	1538	1566	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-1809	CHEMO	1495	mg	5	24	106	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-1809	CHEMO	1898	mg	5	24	106	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2072	CHEMO	3325	mg	7	26	150	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2072	CHEMO	1890	mg	7	26	150	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2072	CHEMO	6280	mg	4	578	619	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2072	CHEMO	64	mg	1	570	570	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	3300	mg	6	22	155	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	751	mg	6	22	155	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	460	mg	1	1622	1622	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	275	mg	1	1622	1622	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	2206	mg	5	1653	1758	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2077	CHEMO	600	mg	5	1653	1758	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2078	CHEMO	3240	mg	6	35	149	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2078	CHEMO	1980	mg	6	35	149	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2079	CHEMO	1800	mg	6	4	125	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2079	CHEMO	3420	mg	6	4	125	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2079	CHEMO	663	mg	9	296	489	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2079	CHEMO	1651	mg	3	2102	2147	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	1750	mg	3	2585	2629	null	Avastin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	300	mg	3	2585	2629	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	2480	mg	8	16	173	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	4400	mg	8	16	173	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	280	mg	4	331	418	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	290	mg	2	939	960	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	1400	mg	2	939	960	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	1020	mg	8	988	1154	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	20400	mg	8	988	1154	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	13200	mg	11	1790	1948	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	660	mg	11	1790	1948	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2081	CHEMO	1325	mg	11	2070	2173	null	AMG 706	RECURRENCE	ORAL	
TCGA-23-2084	CHEMO	4240	mg	8	6	155	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	2200	mg	8	6	155	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	700	mg	6	631	701	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	12600	mg	6	631	701	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	1680	mg	3	1127	1169	null	Rhumab/Ind	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	195	mg	3	1183	1240	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	360	mg	3	1261	1302	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	14	mg	4	1324	1359	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	1615	mg	2	1381	1401	null	Ifosfamide	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	920	mg	2	1381	1401	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	730	mg	1	1425	1425	null	Ifosfamide	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	100	mg	1	1425	1425	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-23-2084	CHEMO	100	mg	2	1457	1485	null	Etoposide (VP16)	PROGRESSION	ORAL	
TCGA-24-0966	CHEMO	1390	mg	5	21	120	null	paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0966	CHEMO	2456	mg	5	21	111	null	carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0966	TARGETED	2457	mg	null	71	120	null	Avastin	ADJUVANT	null	
TCGA-24-0968	CHEMO	2790	mg/m2	5	35	null	null	Carboplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	1378	mg/m2	5	35	null	null	Paclitaxel	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	null	null	1	35	null	null	Doxil	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	null	null	1	35	null	null	Cisplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	null	null	1	35	null	null	Gemzar	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	null	null	4	35	null	null	Topotecan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	null	null	4	35	null	null	Navalbine	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0968	CHEMO	50	mg	null	35	null	null	Cytoxan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0970	CHEMO	1980	mg/m2	8	25	314	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0970	CHEMO	3840	mg/m2	8	25	314	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0970	CHEMO	152	mg/m2	8	25	314	null	Doxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	8	22	610	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	8	22	610	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	2	22	610	null	Gencitabine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	2	22	610	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	3	22	610	null	Topotecan	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0975	CHEMO	null	mg/m2	3	22	610	null	Nevalbine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0979	CHEMO	null	null	8	15	184	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0979	CHEMO	null	null	8	15	184	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0980	CHEMO	1265.5	mg	4	77	178	null	paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0980	CHEMO	2012	mg	4	77	178	null	carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-0981	CHEMO	4698	mg/m2	35	24	932	null	Carboplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	2749	mg/m2	35	24	932	null	Paclitaxel	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	235	mg/m2	35	24	932	null	Doxil	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	23915	mg/m2	35	24	932	null	5FU (fluarourcil)	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	19.8	mg/m2	35	24	932	null	Topotecan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	198	mg/m2	35	24	932	null	Navebine	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	14000	mg/m2	35	24	929	null	Hexalen	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	6400	mg/m2	35	24	932	null	Gemzar	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	240	mg/m2	35	24	932	null	Cisplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	10500	mg/m2	35	24	932	null	Etoposide	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	CHEMO	null	null	35	24	932	null	Docetaxel	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	IMMUNO	8.5 mg	mg/m2	null	853	857	null	BBX-01	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0981	TARGETED	5890 mg	mg/m2	null	630	820	null	Bevacixumab	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-0982	CHEMO	7890	mg/m2	22	14	614	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0982	CHEMO	4	null	22	14	614	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0982	CHEMO	39	mg/m2	22	14	614	null	Topotecan	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0982	CHEMO	390	mg/m2	22	14	614	null	Navelbine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0982	CHEMO	24798	mg/m2	22	14	614	null	Gemzar	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-0982	CHEMO	388	mg/m2	22	14	614	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1103	CHEMO	1920	mg	22	19	1624	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1103	CHEMO	81.6	mg	22	19	1624	null	Topotecan	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1103	CHEMO	816	mg	22	19	1624	null	Navelbine	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1103	CHEMO	786	mg	22	19	1624	null	Taxotere	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1103	CHEMO	4879	mg	22	19	1624	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1104	CHEMO	3396	mg	17	30	1876	null	Paclitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1104	CHEMO	190	mg	17	30	1876	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1104	CHEMO	250	mg	17	30	1876	null	Cisplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1104	CHEMO	2409	mg	17	30	1876	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1105	CHEMO	9045	mg/m2	32	25	1375	null	Carboplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	4100	mg/m2	32	25	1375	null	Paclitaxel	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	48.2	mg/m2	32	25	1375	null	Topotecan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	486	mg/m2	32	25	1375	null	Navelbine	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	21146	mg/m2	32	25	1375	null	Gemzar	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	258	mg/m2	32	25	1375	null	Doxil	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	4500	mg/m2	32	25	1375	null	Cytoxan	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	CHEMO	12	mg/m2	32	25	1375	null	Cisplatin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1105	TARGETED	2001	mg/m2	null	1228	1298	null	Avastin	OTHER: SPECIFY IN NOTES	OTHER: SPECIFY IN NOTES	
TCGA-24-1413	CHEMO	1340	mg	6	34	145	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1413	CHEMO	3864	mg	6	34	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1416	CHEMO	934	mg	8	16	170	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-24-1416	CHEMO	946	mg	8	16	170	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-24-1416	CHEMO	647	mg	8	16	170	null	Taxol	ADJUVANT	IV AND IP	
TCGA-24-1416	CHEMO	422	mg	8	16	170	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-24-1417	CHEMO	2538	mg	8	25	156	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1417	CHEMO	5500	mg	8	25	156	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1418	CHEMO	1510	mg	6	23	161	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1418	CHEMO	2554	mg	6	23	161	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1418	TARGETED	8459	mg	null	43	231	null	Bevacizamab/Placebo	ADJUVANT	null	
TCGA-24-1419	CHEMO	3882	mg	6	17	121	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1419	CHEMO	478	mg	2	-168	null	null	Pacitaxel	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1419	CHEMO	806	mg	6	17	131	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1422	null	null	null	null	null	null	null	null	null	null	
TCGA-24-1423	CHEMO	477	mg	7	21	151	null	Doxorubicin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1423	CHEMO	532	mg	7	21	151	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1423	CHEMO	1703	mg	7	21	151	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1424	CHEMO	1441	mg	6	8	120	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1424	CHEMO	972	mg	6	8	120	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1424	CHEMO	429	mg	6	8	120	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1425	CHEMO	832	mg	6	27	145	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-24-1425	CHEMO	5065	mg	6	27	145	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-24-1425	CHEMO	553	mg	6	27	145	null	Taxol	ADJUVANT	IV AND IP	
TCGA-24-1426	CHEMO	780	mg	6	-8	142	null	Taxoterecin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1426	CHEMO	900	mg	6	-8	142	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1426	CHEMO	720	mg	6	-8	142	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1427	CHEMO	1996	mg	6	14	146	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1427	CHEMO	3848	mg	6	14	146	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1428	CHEMO	650	mg	4	46	null	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1428	CHEMO	750	mg	4	46	null	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-24-1428	CHEMO	480	mg	4	46	null	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	539	mg	6	21	105	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	1252	mg	6	21	105	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	5301	mg	6	21	105	null	Amitostine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	44.88	mg	5	462	546	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	177	mg	3	567	624	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	128	mg	5	652	768	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	1960	mg	5	652	768	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	81	mg	1.5	803	840	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1430	CHEMO	5150	mg	1.5	803	840	null	Gomzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1431	CHEMO	null	null	6	42	147	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1431	CHEMO	null	null	6	42	147	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1431	CHEMO	null	null	3	262	308	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1431	CHEMO	null	null	null	null	null	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1431	CHEMO	null	null	null	329	null	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	284	mg	8	61	244	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	1890	mg	8	61	244	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	16000	mg	8	61	244	null	Gemzet	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	24	mg	2	281	314	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	160	mg	2	343	371	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1434	CHEMO	4200	mg	2	395	426	null	Etoposide	PROGRESSION	ORAL	
TCGA-24-1434	CHEMO	756	mg	2	496	535	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	3590	mg	6	27	149	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	135.9	mg	13	511	771	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	2350	mg	5	814	912	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	286	mg	4	944	1028	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	4500	mg	10	1058	1126	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	263	mg	3	1140	1189	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	6952	mg	3	1140	1189	null	Gemar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	9.63	mg	1	1259	1266	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1435	CHEMO	1848	mg	6	27	149	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1436	CHEMO	2730	mg	5	24	134	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1436	CHEMO	1282	mg	5	24	134	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1436	CHEMO	28.25	mg	3	156	222	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	3310	mg	6	18	123	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	1712	mg	6	18	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	1660	mg	6	976	1084	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	1895	mg	6	976	1084	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	172	mg	2	976	1084	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	49.4	mg	6	1270	1383	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	508	mg	6	1270	1383	null	Navelbine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	20684	mg	5	1465	1558	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	277	mg	5	1465	1558	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	2275	mg	17	1600	1733	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1463	CHEMO	168	mg	2	1742	1791	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1464	CHEMO	1937	mg	7	28	163	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1464	CHEMO	5555	mg	7	28	163	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1464	CHEMO	8.44	mg	1	342	343	null	Toptecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	3502	mg	6	12	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	1715	mg	6	12	145	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	1904	mg	7	483	680	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	3820	mg	7	483	680	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	3110	mg	6	880	1020	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	1564	mg	6	880	1020	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1466	CHEMO	57.6	mg	6	1081	1216	null	Topetecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1466	HORMONAL	20	mg/day	null	670	852	null	Tamoxifen	RECURRENCE	ORAL	
TCGA-24-1466	HORMONAL	null	null	null	1227	null	null	Tamoxifen	PROGRESSION	ORAL	
TCGA-24-1467	CHEMO	2650	mg	6	6	109	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	4565	mg	6	6	109	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	1780	mg	6	1276	1391	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	1275	mg	2	1276	1391	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	400	mg	4	1276	1391	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	1620	mg	6	1804	1908	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	600	mg	6	1804	1908	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	60	mg	6	2321	2295	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	1350	mg	8	2561	2736	null	Doxetaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	115	mg	8	2561	2736	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	50	mg	null	2818	2889	null	Cytoxen	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	600	mg	6	2321	2295	null	Navelbine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	240	mg	3	2476	2531	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	240	mg	3	2988	3058	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	CHEMO	21	mg	2	3072	3100	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	HORMONAL	20	mg	null	2362	2457	null	Tamoxifen	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1467	HORMONAL	20	mg	null	2757	null	null	Tamoxifen	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1467	TARGETED	3610	mg	null	2818	2889	null	Bevacizumab	ADJUVANT	ORAL	
TCGA-24-1467	TARGETED	8871	mg	null	2988	3058	null	Bevacizumab	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1469	CHEMO	null	null	6	null	122	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1469	CHEMO	null	null	6	null	122	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1470	CHEMO	110	mg	4	17	82	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-24-1470	CHEMO	475	mg	4	17	82	null	Docetaxel	ADJUVANT	IV AND IP	
TCGA-24-1470	CHEMO	593	mg	4	17	82	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-24-1471	null	null	null	null	null	null	null	null	null	null	
TCGA-24-1474	CHEMO	4050	mg	6	383	123	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1474	CHEMO	1962	mg	6	383	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1474	CHEMO	57	mg	5	349	431	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1474	CHEMO	2365	mg	7	454	634	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1474	CHEMO	302	mg	7	454	634	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	3080	mg	8	18	203	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	12.6	mg	8	18	203	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	1356	mg	8	18	203	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	2100	mg	9	243	470	null	Doxil	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	2500	mg	4	533	638	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1544	CHEMO	595	mg	2	777	495	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	215	mg	2	1203	1237	null	Navelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	2520	mg	10	14	284	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	5750	mg	10	14	284	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	42	mg	5	866	950	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	165	mg	3	972	1027	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	1476	mg	6	1055	1169	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1545	CHEMO	3068	mg	6	1055	1169	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1546	CHEMO	null	null	null	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1546	CHEMO	null	null	null	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	1750	mg	6	6	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	4790	mg	6	6	123	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	10	mg	2	-144	-123	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	250	mg	2	-144	-123	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	197	mg	3	272	327	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	null	null	null	365	457	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	null	null	null	365	457	null	Navelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	360	mg	3	475	488	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	1750	mg	6	6	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1548	CHEMO	4790	mg	6	6	123	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	6	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	6	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	6	null	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	6	null	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	7	null	null	null	Toptecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Gemzan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	VP16	PROGRESSION	null	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Carboplatin	PROGRESSION	null	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Cisplatin	PROGRESSION	null	
TCGA-24-1549	CHEMO	null	null	null	1518	null	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	2	null	null	null	Xeloda	PROGRESSION	ORAL	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1549	CHEMO	null	null	null	null	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	2070	mg	7	8	174	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	165	mg	7	8	174	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	405	mg	4	902	965	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	4200	mg	6	986	1107	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	837	mg	3	1164	1211	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	1950	mg	3	1164	1211	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1550	CHEMO	64	mg	1	1233	1233	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	4140	mg	7	10	135	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	2080	mg	7	10	135	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	12.5	mg	1	790	790	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	3600	mg	6	842	975	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	160	mg	2	1227	1254	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	3020	mg	19	1289	1437	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1551	CHEMO	80	mg	1	1549	1549	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	null	null	6	61	638	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	null	null	6	61	638	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	null	null	null	487	587	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	350	mg	5	728	851	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	822	mg	4	876	664	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	4325	mg	4	876	664	null	Amitostine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1552	CHEMO	1925	mg	5	1044	1170	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	2715	mg	6	17	154	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	1732	mg	6	17	154	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	3360	mg	6	566	735	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	1740	mg	6	566	735	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	70.2	mg	3	864	1283	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	448	mg	9	944	1224	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	29746	mg	9	944	1224	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	3360	mg	12	1309	1623	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	3800	mg	12	1309	1623	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	CHEMO	6000	mg	2	1659	1691	null	Xeloda	PROGRESSION	ORAL	
TCGA-24-1553	CHEMO	63	mg	1	1735	1735	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1553	HORMONAL	20	mg	null	1243	1293	null	Tamoxifen	PROGRESSION	ORAL	
TCGA-24-1555	CHEMO	null	null	6	1949	2040	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	6	1949	2040	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	16	null	null	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	6	null	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	6	null	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	8	2252	2405	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	8	2252	2405	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	4	2496	2618	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	4	2496	2618	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	4	2635	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1555	CHEMO	null	null	4	2635	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	6	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	4	null	null	null	Cytoxan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	2	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	7	549	638	null	Toptecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	6	null	null	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	5	1734	1832	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1556	CHEMO	null	null	5	1734	1832	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	3392	mg	8	27	281	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	6250	mg	12	27	281	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	14.7	mg	4	27	281	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	32.4	mg	3	300	347	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	10980	mg	3	368	445	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	175	mg	3	368	445	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	2600	mg	8	462	623	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	5350	mg	8	462	623	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	1300	mg	4	644	727	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	45.5	mg	3	754	798	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	670	mg	7	875	1008	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	12240	mg	7	875	1008	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	424	mg	3	1027	1069	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	1300	mg	4	1090	1154	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	CHEMO	2315	mg	4	1090	1154	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1557	HORMONAL	null	null	null	765	873	null	null	PALLIATIVE	null	
TCGA-24-1558	CHEMO	14.4	mg	10	37	247	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	43.75	mg	10	37	247	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	1800	mg	10	37	247	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	3600	mg	4	316	382	null	Lily	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	524	mg	4	316	382	null	Taxotere	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	11810	mg	4	515	588	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1558	CHEMO	277	mg	4	403	487	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	1620	mg	6	15	117	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	4620	mg	6	15	117	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	48	mg	5	398	481	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	48	mg	5	398	481	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	7220	mg	6	509	614	null	Amitostin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	1730	mg	6	509	614	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	3100	mg	6	509	614	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	15000	mg	3	635	726	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	200	mg	3	635	726	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	2875	mg	6	757	901	null	Carboplatin	RECURRENCE	OTHER: SPECIFY IN NOTES	
TCGA-24-1560	CHEMO	4650	mg	6	757	901	null	Etopside	RECURRENCE	OTHER: SPECIFY IN NOTES	
TCGA-24-1560	CHEMO	210000	mg	5	931	650	null	Xeloda	PROGRESSION	ORAL	
TCGA-24-1560	CHEMO	2730	mg	5	1043	1189	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1560	CHEMO	1640	mg	3	1216	1258	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	6	21	151	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	6	21	151	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	8	257	405	null	Topotecan	RECURRENCE	null	
TCGA-24-1562	CHEMO	null	null	1	850	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	1	850	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	375	mg	5	530	642	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	null	677	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	null	677	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1562	CHEMO	null	null	10	null	1156	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	3450	mg	6	22	143	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	1910	mg	6	22	143	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	135	mg	14	408	676	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	1050	mg	3	728	804	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	2820	mg	3	811	867	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	181	mg	3	811	867	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	3310	mg	8	888	1061	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	24.7	mg	3	1182	1238	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	CHEMO	459	mg	1	1402	1402	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1563	HORMONAL	20	mg/day	null	1087	1181	null	Tamoxifen	PROGRESSION	ORAL	
TCGA-24-1564	CHEMO	779	mg	6	8	116	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	1396	mg	6	8	116	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	1200	mg	4	248	295	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	5080	mg	4	248	295	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	5080	mg	4	248	295	null	Amitostine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	32.5	mg	4	333	406	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	136	mg	2	435	463	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	1496	mg	11	499	568	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1564	CHEMO	1500	mg	2	589	624	null	VP16	PROGRESSION	ORAL	
TCGA-24-1564	CHEMO	2462	mg	2	589	624	null	Gezmar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1564	HORMONAL	20	mg	null	736	null	null	Tamoxifen	PROGRESSION	ORAL	
TCGA-24-1565	CHEMO	1389	mg	6	39	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1565	CHEMO	774	mg	6	39	123	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1565	CHEMO	null	null	null	178	null	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1567	CHEMO	null	null	6	41	153	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1567	CHEMO	null	null	6	41	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1567	CHEMO	null	null	null	1065	null	null	Topecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	6	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	6	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	6	1095	1181	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	6	1095	1181	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	8	1356	4803	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	8	1356	4803	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	9	null	1853	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	9	1887	1979	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	9	1887	1979	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	28	2010	2191	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	null	2222	2436	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	null	2556	2617	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1603	CHEMO	null	null	1	2556	2617	null	Taxotere	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1604	CHEMO	null	null	null	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1604	CHEMO	null	null	null	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1604	CHEMO	null	null	null	null	null	null	null	RECURRENCE	null	
TCGA-24-1604	CHEMO	null	null	null	null	null	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1614	CHEMO	null	null	8	22	182	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1614	CHEMO	null	null	8	22	182	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1614	CHEMO	null	null	11	638	882	null	Topotecan	RECURRENCE	null	
TCGA-24-1614	CHEMO	null	null	11	638	882	null	Navelbine	RECURRENCE	null	
TCGA-24-1614	CHEMO	null	null	6	1004	1127	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1614	CHEMO	null	null	6	1004	1127	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1614	CHEMO	null	null	4	1278	1443	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	8	18	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	8	18	153	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Gemzar	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1616	CHEMO	null	null	null	null	null	null	Cisplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-24-1842	CHEMO	2901	mg	4	24	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1842	CHEMO	1363	mg	4	24	null	null	Paclintaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1842	TARGETED	3799	mg	null	24	null	null	Bevacizumiab	ADJUVANT	null	
TCGA-24-1843	CHEMO	373	mg	5	20	134	null	Taxol	ADJUVANT	IV AND IP	
TCGA-24-1843	CHEMO	582	mg	5	20	null	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-24-1843	CHEMO	2957	mg	5	20	134	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-24-1844	CHEMO	405	mg	5	24	134	null	Docetaxel	ADJUVANT	IV AND IP	
TCGA-24-1844	CHEMO	1285	mg	5	24	134	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-24-1844	CHEMO	2660	mg	5	24	134	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-24-1845	CHEMO	1169	mg	6	72	123	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-24-1845	CHEMO	603	mg	6	72	123	null	Doxetaxel	ADJUVANT	IV AND IP	
TCGA-24-1845	CHEMO	469	mg	6	72	123	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-24-1845	CHEMO	118	mg	6	72	123	null	Pacliatxel	ADJUVANT	IV AND IP	
TCGA-24-1846	CHEMO	3800	mg	5	43	175	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1846	CHEMO	1173	mg	5	43	175	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1847	CHEMO	733	mg	6	31	142	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1847	CHEMO	862	mg	6	31	142	null	Ciplastin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-24-1847	CHEMO	687	mg	6	31	142	null	Taxol	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-24-1849	CHEMO	3306	mg	6	35	140	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1849	CHEMO	696	mg	6	35	140	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1850	CHEMO	3138	mg	6	34	137	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1850	CHEMO	706	mg	6	34	137	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-24-1920	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-1923	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-1924	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-1927	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-1928	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-1930	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2019	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2020	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2023	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2024	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2026	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2027	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2029	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2030	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2033	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2035	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2036	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2038	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2254	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2260	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-24-2261	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-25-1312	null	null	null	null	null	null	null	null	null	null	
TCGA-25-1313	CHEMO	null	null	6	29	150	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1313	CHEMO	null	null	null	29	150	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1313	CHEMO	null	null	5	394	546	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1314	CHEMO	null	null	6	31	null	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1314	CHEMO	null	null	2	31	null	null	Cisplatinum	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1314	CHEMO	null	null	7	273	425	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1314	CHEMO	null	null	8	31	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1315	CHEMO	null	null	6	30	153	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1315	CHEMO	null	null	null	153	334	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1315	CHEMO	null	null	null	153	334	null	Carbo	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1315	CHEMO	null	null	null	143	334	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1315	CHEMO	null	null	6	30	153	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1316	CHEMO	null	null	null	61	214	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1316	CHEMO	null	null	6	276	406	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1316	CHEMO	null	null	null	61	214	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1317	CHEMO	null	null	1	0	761	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1317	CHEMO	null	null	1	0	761	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1318	CHEMO	null	null	6	30	122	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1318	CHEMO	null	null	6	30	122	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1318	CHEMO	null	null	4	212	273	null	Topetecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1319	CHEMO	null	null	6	61	null	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1319	CHEMO	null	null	6	61	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1320	CHEMO	null	null	8	28	180	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1320	CHEMO	null	null	8	28	180	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1320	CHEMO	null	null	8	28	180	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1320	CHEMO	null	null	7	423	606	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1321	CHEMO	null	null	8	28	180	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1321	CHEMO	null	null	8	28	180	null	Gemzar	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1321	CHEMO	null	null	8	28	180	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1321	CHEMO	null	null	2	453	497	null	Topotecan	RECURRENCE	null	
TCGA-25-1322	CHEMO	null	null	3	30	91	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1322	CHEMO	null	null	3	30	91	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1323	CHEMO	null	null	2	365	365	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1323	CHEMO	null	null	5	30	122	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1323	CHEMO	null	null	5	30	122	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1324	CHEMO	null	null	null	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1324	CHEMO	null	null	null	null	null	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1325	null	null	null	null	null	null	null	null	null	null	
TCGA-25-1326	CHEMO	null	null	8	30	152	null	Topetecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1326	CHEMO	null	null	8	30	152	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1326	CHEMO	null	null	8	30	152	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1326	CHEMO	null	null	8	30	152	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1326	CHEMO	null	null	null	395	517	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1328	CHEMO	null	null	null	275	395	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1328	CHEMO	null	null	null	275	395	null	Cytoxan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1328	CHEMO	null	null	null	275	395	null	Carbo	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1328	CHEMO	null	null	null	30	214	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1328	CHEMO	null	null	null	30	214	null	Carbo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1329	null	null	null	null	null	null	null	null	null	null	
TCGA-25-1623	CHEMO	null	null	null	null	null	null	A202171 Protocol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1623	CHEMO	null	null	6	16	138	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1623	CHEMO	null	null	6	16	138	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1625	CHEMO	null	null	8	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1625	CHEMO	null	null	8	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1626	CHEMO	null	null	7	20	207	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1626	CHEMO	null	null	7	20	207	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1626	CHEMO	null	null	7	20	207	null	Gemzar	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1626	CHEMO	null	null	1	319	319	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1627	null	null	null	null	null	null	null	null	null	null	
TCGA-25-1628	CHEMO	null	null	8	35	181	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1628	CHEMO	null	null	8	35	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1628	CHEMO	null	null	2	298	350	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1630	CHEMO	null	null	6	33	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1630	CHEMO	null	null	6	33	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1631	null	null	null	null	null	null	null	null	null	null	
TCGA-25-1632	CHEMO	null	null	8	82	200	null	Doxil	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1632	CHEMO	null	null	8	82	200	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1632	CHEMO	null	null	8	82	200	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1632	CHEMO	null	null	8	566	719	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1632	CHEMO	null	null	8	566	719	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1633	CHEMO	null	null	8	26	184	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1633	CHEMO	null	null	8	26	184	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1633	CHEMO	null	null	8	26	184	null	Gemzar	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1633	CHEMO	null	null	8	617	740	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1633	CHEMO	null	null	8	617	740	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1634	CHEMO	null	null	8	29	206	null	Toptecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1634	CHEMO	null	null	8	29	206	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1634	CHEMO	null	null	8	29	206	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1634	HORMONAL	null	null	null	380	843	null	Tamoxifen	RECURRENCE	null	
TCGA-25-1635	CHEMO	null	null	8	24	233	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1635	CHEMO	null	null	8	24	233	null	Gemzar	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1635	CHEMO	null	null	8	24	233	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1635	CHEMO	null	null	4	614	741	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1635	CHEMO	null	null	4	614	741	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1870	CHEMO	null	null	4	31	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1870	CHEMO	null	null	4	31	null	null	Cytoxan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1870	CHEMO	null	null	2	150	null	null	Cytoxan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1870	CHEMO	null	null	2	150	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-25-1871	CHEMO	null	null	6	233	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1871	CHEMO	null	null	6	47	null	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1871	CHEMO	null	null	6	47	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1877	CHEMO	null	null	null	null	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1877	CHEMO	null	null	null	31	null	null	Cytoxan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1877	CHEMO	null	null	null	31	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1878	CHEMO	null	null	5	976	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-25-1878	CHEMO	null	null	6	61	null	null	Cytoxan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1878	CHEMO	null	null	6	61	null	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-25-1878	CHEMO	null	null	5	976	null	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1688	CHEMO	null	null	null	null	null	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1688	CHEMO	null	null	null	null	null	null	Cytoxan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1690	null	null	null	null	null	null	null	null	null	null	
TCGA-29-1691	CHEMO	null	null	6	null	153	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1691	CHEMO	null	null	6	null	153	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1693	CHEMO	3430	mg	8	18	190	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1693	CHEMO	2240	mg	8	18	190	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1694	null	null	null	null	null	null	null	null	null	null	
TCGA-29-1695	null	null	null	null	null	null	null	null	null	null	
TCGA-29-1696	CHEMO	2550	mg	8	17	171	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1696	CHEMO	5472	mg	8	17	171	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1697	CHEMO	4512	mg	7	28	181	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1697	CHEMO	11184	mg	4	28	91	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1697	CHEMO	1246	mg	4	110	181	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1698	CHEMO	5600	mg	9	8	236	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1698	CHEMO	2603	mg	9	8	236	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1699	null	null	null	null	null	null	null	null	null	null	
TCGA-29-1701	CHEMO	1280	mg	5	31	160	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1701	CHEMO	4505	mg	5	31	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1702	CHEMO	6	AUC	6	null	198	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1702	CHEMO	null	null	null	null	null	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1703	CHEMO	1595	mg	6	16	162	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1703	CHEMO	4081	mg	6	16	162	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1705	CHEMO	5630	mg	9	13	524	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1705	CHEMO	1050	mg	3	13	55	null	paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1705	CHEMO	300	mg	2	13	55	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1707	CHEMO	3840	mg	6	24	142	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1707	CHEMO	1789	mg	6	24	142	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1710	CHEMO	3140	mg	5	108	580	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1710	CHEMO	900	mg	3	108	150	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1710	CHEMO	300	mg	2	31	52	null	Oxaliplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1710	CHEMO	260	mg	2	31	52	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1710	TARGETED	1870	mg	null	31	52	null	Bevacizumab	ADJUVANT	null	
TCGA-29-1711	CHEMO	150	mg	6	30	136	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1711	CHEMO	170	mg	6	30	136	null	Oxaliplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1711	TARGETED	1863	mg	null	30	234	null	Bevacizumab	ADJUVANT	null	
TCGA-29-1761	CHEMO	null	null	3	62	215	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1761	CHEMO	null	null	3	null	215	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	null	null	null	7	151	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	null	null	null	7	151	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	null	null	6	1386	1513	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	80	mg	3	2166	2229	null	Doxorubicin HCI Liiposomal	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	400	mg	8	2255	2417	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	60	mg	6	2438	2487	null	Topotecan HCL	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1762	CHEMO	150	mg	3	2508	2554	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1763	CHEMO	3175	mg	5	15	99	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1763	CHEMO	1645	mg	5	15	99	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1764	CHEMO	1050	mg	3	111	167	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1764	CHEMO	12000	mg	6	15	87	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1764	CHEMO	4581	mg	7	15	167	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1766	CHEMO	19590	mg	11	38	195	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1766	CHEMO	1580	mg	4	97	188	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1768	CHEMO	816	mg	5	19	103	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1768	CHEMO	348	mg	6	19	124	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1768	CHEMO	675	mg	9	551	719	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1768	CHEMO	1200	mg	9	551	719	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1768	CHEMO	80	mg	3	827	915	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-29-1768	TARGETED	1493	mg	null	40	252	null	Bevacizumab or placebo	ADJUVANT	null	
TCGA-29-1769	CHEMO	318	mg	1	20	20	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1769	CHEMO	870	mg	1	20	20	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1769	CHEMO	300	mg	6	42	150	null	Paciltaxel	ADJUVANT	IV AND IP	
TCGA-29-1769	CHEMO	130	mg	6	42	150	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-29-1769	IMMUNO	2	mg	null	206	null	null	Abagovomab vs Placebo	ADJUVANT	null	
TCGA-29-1770	CHEMO	300	mg	3	19	68	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	630	mg	3	19	68	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	null	null	2	741	762	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	100	mg	3	87	136	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	690	mg	3	87	136	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	650	mg	6	384	546	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1770	CHEMO	1370	mg	6	384	546	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1770	TARGETED	null	null	null	741	762	null	Avastin	RECURRENCE	null	
TCGA-29-1771	CHEMO	319	mg	7	601	728	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1771	CHEMO	245	mg	7	601	728	null	Pacilatxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1771	CHEMO	345	mg	6	27	139	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1771	CHEMO	200	mg	6	27	139	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1771	IMMUNO	2	mg	null	188	594	null	Abagovomag vs Placebo	ADJUVANT	null	
TCGA-29-1771	TARGETED	695	mg	null	601	728	null	Bevacizumab	RECURRENCE	null	
TCGA-29-1774	CHEMO	1425	mg	5	247	379	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-29-1774	CHEMO	340	mg	1	13	13	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1774	CHEMO	410	mg	1	36	36	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1774	CHEMO	1075	mg	1	85	85	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1775	CHEMO	2040	mg	6	29	166	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1775	CHEMO	4290	mg	6	29	166	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1775	CHEMO	11694	mg	10	114	320	null	Bevacizumab vs Placebo	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1776	null	null	null	null	null	null	null	null	null	null	
TCGA-29-1777	CHEMO	740	mg	6	87	303	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1777	CHEMO	660	mg	1	325	325	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1777	CHEMO	70	mg	1	346	336	null	Doxorubicin HCL	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1778	CHEMO	110	mg	2	101	125	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1778	CHEMO	410	mg	2	101	125	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1778	CHEMO	325	mg	4	17	80	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1778	CHEMO	325	mg	4	17	80	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1778	CHEMO	500	mg	4	17	80	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1781	CHEMO	2970	mg	6	52	254	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1781	CHEMO	2322	mg	6	52	254	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1783	CHEMO	4536	mg	6	29	155	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-29-1783	CHEMO	1623	mg	6	29	155	null	Paclitaxel	ADJUVANT	IV AND IP	
TCGA-29-1783	TARGETED	9750	mg	null	51	283	null	Bevacizumab or Placebo	ADJUVANT	null	
TCGA-29-1784	CHEMO	3330	mg	6	17	136	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1784	CHEMO	270	mg	1	17	17	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1784	CHEMO	300	mg	1	59	59	null	Paclitaxel; Albumin-Bount	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1784	CHEMO	2480	mg	1	23	24	null	Gemcitabine HCI	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	610	mg	2	51	73	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	610	mg	4	94	156	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	300	mg	4	94	156	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	560	mg	1	496	496	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	330	mg	1	496	496	null	Paciltaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	610	mg	5	521	612	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-29-1785	CHEMO	110	mg	5	521	612	null	Docetaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	175	mg/m2	6	15	123	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	5	null	6	15	123	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	40	mg/m2	6	314	417	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	3	mg/m2	1	424	521	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	343	mg/m2	5	555	700	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	175	mg/m2	5	555	700	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	278	mg/m2	5	555	700	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	700	mg/m2	7	906	955	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	30	mg/m2	7	906	955	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	50	mg	1	973	990	null	VP 16	RECURRENCE	ORAL	
TCGA-30-1714	CHEMO	343	mg/m2	2	1002	1075	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	CHEMO	135	mg/m2	2	1002	1081	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1714	HORMONAL	null	null	null	246	283	null	Armidex	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1718	CHEMO	null	null	null	null	null	null	Hexalin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1718	CHEMO	null	null	8	31	178	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1718	CHEMO	null	null	11	206	492	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1718	CHEMO	null	null	null	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1718	CHEMO	null	null	null	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1718	HORMONAL	null	null	null	865	896	null	Tamoxifen	ADJUVANT	null	
TCGA-30-1853	CHEMO	5	AUC	6	669	778	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1853	CHEMO	5	AUC	6	42	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1853	CHEMO	175	mg/m2	6	42	126	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1853	CHEMO	175	mg/m2	6	669	778	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1853	CHEMO	580	mg/m2	3	886	932	null	Trabectedin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1853	CHEMO	40	mg/m2	null	945	1011	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1855	null	null	null	null	null	null	null	null	null	null	
TCGA-30-1856	CHEMO	175	mg/m2	9	17	194	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	5	null	9	17	194	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	1000	mg/m2	9	17	194	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	null	null	9	17	194	null	Adriamycin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	null	null	9	17	194	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	30	mg/m2	4	271	299	null	Taxotere	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	30	mg	1	338	462	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	20	mg/m2	1	338	462	null	Navelbine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1856	CHEMO	50	mg/m2	null	338	462	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1856	HORMONAL	40	mg	null	229	null	null	Tamoxifen	ADJUVANT	null	
TCGA-30-1857	null	null	null	null	null	null	null	null	null	null	
TCGA-30-1859	CHEMO	175	mg/m2	9	30	198	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	1000	mg/m2	9	30	198	null	Gemcitabine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	5	AUC	9	30	198	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	25	mg/m2	9	30	198	null	Adriamycin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	1.25	mg/m2	9	30	198	null	Topotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	500	mg/m2	8	368	593	null	Trabectedin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	5	AUC	5	982	1102	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	null	null	1	1103	1130	null	Sargramostin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	40	mg/m2	2	1161	1196	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	80	mg/m2	null	1213	1376	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1859	CHEMO	null	null	null	1334	1379	null	Cytoxan	PROGRESSION	ORAL	
TCGA-30-1859	HORMONAL	null	null	null	1134	1015	null	Armidex	PROGRESSION	null	
TCGA-30-1860	CHEMO	40	mg	3	413	561	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	5	AUC	7	22	207	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	175	mg/m2	7	22	207	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	5	AUC	6	744	915	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	750	mg/m2	6	744	915	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	4	mg/m2	6	915	957	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	70	mg/m2	12	994	1069	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	15	mg/m2	5	1191	1246	null	Navelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1860	CHEMO	10	mg/kg	null	1191	1246	null	Avastin	PROGRESSION	ORAL	
TCGA-30-1861	null	null	null	null	null	null	null	null	null	null	
TCGA-30-1862	null	null	null	null	null	null	null	null	null	null	
TCGA-30-1866	CHEMO	null	null	6	264	null	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	6	19	125	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	6	19	125	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	8	null	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	8	null	null	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	null	null	null	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	null	null	null	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1866	CHEMO	null	null	null	null	null	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1867	null	null	null	null	null	null	null	null	null	null	
TCGA-30-1880	CHEMO	40	mg/m2	6	357	497	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	5	null	6	46	152	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	175	mg/m2	6	46	152	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	5	AUC	6	718	823	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	175	mg/m2	6	718	823	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	700	mg/m2	null	1106	1228	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	5	AUC	9	1400	1610	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	175	mg/m2	9	1400	1610	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	3.6	mg/m2	null	1642	1656	null	CBP501	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1880	CHEMO	10	mg/kg	null	1660	1722	null	Avastin	PROGRESSION	ORAL	
TCGA-30-1880	CHEMO	20	mg/m2	8	1660	1722	null	Navelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1887	CHEMO	800	mg/m2	null	328	433	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1887	CHEMO	175	mg/m2	6	27	133	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1887	CHEMO	5	AUC	6	27	133	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1887	CHEMO	3	mg/m2	3	453	481	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1887	CHEMO	64	mg/m2	null	502	671	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	40	mg/m2	6	189	321	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	5	AUC	7	15	141	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	175	mg/m2	7	15	141	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	50	mg	2	358	386	null	Cytoxan	PROGRESSION	ORAL	
TCGA-30-1891	CHEMO	700	mg	5	400	453	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	700	mg/m2	null	460	526	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	5	AUC	4	460	526	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	75	mg/m2	5	554	638	null	Cisplatin	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-30-1891	CHEMO	80	mg/m2	4	666	694	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	3	mg/m2	12	701	890	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	CHEMO	25	mg/m2	6	855	890	null	Navelbine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1891	IMMUNO	10	mg/kg	null	358	386	null	Avastin	PROGRESSION	null	
TCGA-30-1892	CHEMO	6	AUC	6	10	132	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	null	null	null	428	208	null	Gemcitabine	PROGRESSION	null	
TCGA-30-1892	CHEMO	null	null	null	601	754	null	Carboplatin	PROGRESSION	null	
TCGA-30-1892	CHEMO	null	null	null	null	null	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	null	null	null	862	null	null	Altima	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	50	mg	null	1113	1197	null	Cytoxin	PROGRESSION	ORAL	
TCGA-30-1892	CHEMO	70	mg/m2	null	1197	1258	null	Taxol	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	5	AUC	6	1265	1384	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	10	null	4	1428	1449	null	Catumaxumab	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-30-1892	IMMUNO	15	mg/kg	null	1134	1197	null	Avastin	PROGRESSION	null	
TCGA-30-1892	CHEMO	null	null	5	253	419	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-30-1892	CHEMO	null	null	6	10	132	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1944	CHEMO	4200	mg	6	7	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1944	CHEMO	1650	mg	6	7	126	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1944	CHEMO	345	mg	3	153	null	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-31-1944	CHEMO	835	mg	3	153	null	null	Paciltaxel	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-31-1944	CHEMO	3300	mg	6	721	841	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1944	CHEMO	1650	mg	6	721	841	null	Paciltaxel	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1944	CHEMO	null	null	null	944	1096	null	Megace	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-31-1944	CHEMO	null	null	null	1032	null	null	AZD 2281	PROGRESSION	ORAL	
TCGA-31-1944	HORMONAL	9140	mg	null	479	944	null	Tamoxifen	RECURRENCE	null	
TCGA-31-1946	CHEMO	1400	mg	2	22	43	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	260	mg	2	22	43	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	12000	mg	4	64	148	null	Gemcitabine	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	2200	mg	4	64	148	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	144	mg	3	687	743	null	Liosomal Docorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	180	mg	3	687	743	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1946	CHEMO	1500	mg	3	771	828	null	Carboplatin	OTHER: SPECIFY IN NOTES	INTRAVENOUS (IV)	
TCGA-31-1950	CHEMO	3300	mg	6	33	144	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1950	CHEMO	1440	mg	18	431	571	null	Paciltaxel	RECURRENCE	INTRAVENOUS (IV)	
TCGA-31-1950	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-31-1951	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-31-1953	CHEMO	1350	mg	3	23	65	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1953	CHEMO	840	mg	3	23	65	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1953	CHEMO	null	null	null	100	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1953	CHEMO	null	null	null	100	null	null	Paciltaxle	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1955	CHEMO	3600	mg	6	42	147	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1955	CHEMO	1560	mg	6	42	147	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1955	CHEMO	null	null	null	1189	null	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1955	CHEMO	null	null	null	1189	null	null	Paciltaxle	PROGRESSION	INTRAVENOUS (IV)	
TCGA-31-1956	CHEMO	5150	mg	7	34	187	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1956	CHEMO	1590	mg	7	34	187	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1959	CHEMO	null	null	null	26	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-31-1959	CHEMO	null	null	null	26	null	null	Paciltaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-36-1568	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1569	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1570	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1571	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1574	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1575	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1576	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1577	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1578	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1580	null	null	null	null	null	null	null	null	null	null	
TCGA-36-1581	null	null	null	null	null	null	null	null	null	null	
TCGA-57-1582	CHEMO	null	null	6	30	183	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-57-1582	CHEMO	null	null	6	30	183	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-57-1582	CHEMO	null	null	null	273	null	null	Patupilone	PROGRESSION	null	
TCGA-57-1582	CHEMO	null	null	null	457	518	null	Doxil	PROGRESSION	INTRAVENOUS (IV)	
TCGA-57-1582	CHEMO	null	null	null	518	610	null	Topotecan	PROGRESSION	null	
TCGA-57-1582	CHEMO	null	null	null	610	731	null	Carboplatin	PROGRESSION	null	
TCGA-57-1582	CHEMO	null	null	null	610	731	null	Gemzar	PROGRESSION	null	
TCGA-57-1583	CHEMO	null	null	null	37	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-57-1583	CHEMO	null	null	null	37	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-57-1584	CHEMO	175	mg/m2	null	573	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-57-1584	CHEMO	6	null	null	573	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-57-1585	CHEMO	null	null	null	30	53	null	Carboplatin	ADJUVANT	null	
TCGA-57-1585	CHEMO	null	null	null	30	53	null	Taxol	ADJUVANT	null	
TCGA-57-1586	CHEMO	null	null	8	49	163	null	Taxol	ADJUVANT	null	
TCGA-57-1586	CHEMO	null	null	8	49	163	null	Carboplatin	ADJUVANT	null	
TCGA-57-1586	CHEMO	null	null	4	259	null	null	Gemzar	PROGRESSION	null	
TCGA-57-1586	CHEMO	null	null	4	259	null	null	Cisplatin	PROGRESSION	null	
TCGA-57-1586	CHEMO	null	null	3	323	406	null	Doxil	PROGRESSION	null	
TCGA-57-1586	CHEMO	null	null	null	433	542	null	Topotecan	PROGRESSION	null	
TCGA-57-1586	CHEMO	null	null	1	553	null	null	Carboplatin	PROGRESSION	null	
TCGA-57-1586	CHEMO	null	null	1	553	null	null	Taxol	PROGRESSION	null	
TCGA-57-1992	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-57-1993	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-57-1994	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-61-1722	CHEMO	30	mg	3	103	173	null	Decodron	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1722	CHEMO	3000	mg	3	103	173	null	Cytoxan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1722	CHEMO	29	mg	3	103	170	null	Mitoxantrone	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1722	CHEMO	6	mg	3	103	173	null	Vincristine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1724	CHEMO	null	null	null	287	null	null	Cisplatin	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-61-1724	CHEMO	null	null	null	null	null	null	Gemcitabine	ADJUVANT	null	
TCGA-61-1724	CHEMO	null	null	null	null	null	null	Carboplatin	ADJUVANT	null	
TCGA-61-1724	CHEMO	null	null	null	368	null	null	Doxil	PROGRESSION	null	
TCGA-61-1724	CHEMO	null	null	null	513	null	null	Taxotere	PROGRESSION	null	
TCGA-61-1724	CHEMO	null	null	null	607	null	null	Gemzar	PROGRESSION	null	
TCGA-61-1725	CHEMO	1548	mg	6	44	157	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1725	CHEMO	585	mg	6	44	157	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1725	CHEMO	456	mg	6	44	157	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1725	CHEMO	3204	mg	12	234	576	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1725	CHEMO	8550	mg	6	907	null	null	Avastin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1725	CHEMO	4368	mg	6	907	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1725	CHEMO	2400	mg	6	907	null	null	Gamzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1727	CHEMO	600	mg	6	62	153	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1727	CHEMO	2250	mg	6	62	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1728	CHEMO	1920	mg	20	246	848	null	SNS 595	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1728	CHEMO	5280	mg	8	43	204	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1728	CHEMO	2000	mg	8	43	204	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1730	null	null	null	null	null	null	null	null	null	null	
TCGA-61-1733	CHEMO	3924	mg	6	22	126	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1733	CHEMO	638	mg	6	22	126	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1733	CHEMO	482	mg	6	230	372	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1733	CHEMO	390	mg	6	483	624	null	Taxol	PROGRESSION	IV AND IP	
TCGA-61-1733	CHEMO	720	mg	6	483	624	null	Cisplatin	PROGRESSION	IV AND IP	
TCGA-61-1733	CHEMO	582	mg	6	483	624	null	Taxotere	PROGRESSION	IV AND IP	
TCGA-61-1734	CHEMO	null	null	6	46	158	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1734	CHEMO	null	null	6	46	158	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1736	CHEMO	null	null	null	null	null	null	Gemzar	RECURRENCE	null	
TCGA-61-1736	CHEMO	null	null	6	34	138	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1736	CHEMO	null	null	6	34	138	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1736	CHEMO	null	null	null	null	null	null	Cisplatin	RECURRENCE	null	
TCGA-61-1736	CHEMO	null	null	null	943	null	null	Doxil	PROGRESSION	null	
TCGA-61-1737	CHEMO	480	mg	4	null	null	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1737	CHEMO	2600	mg	4	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1737	CHEMO	270	mg	3	null	null	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-61-1737	CHEMO	372	mg	3	null	null	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1737	CHEMO	198	mg	3	null	null	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1737	HORMONAL	19000	mg/day	null	null	null	null	Tamoxifen	ADJUVANT	null	
TCGA-61-1738	CHEMO	2376	mg	6	21	135	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1738	CHEMO	5	AUC	6	21	135	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1738	CHEMO	364	mg	4	198	276	null	Cisplatin	ADJUVANT	INTRA-PERITONEAL (IP)	
TCGA-61-1738	CHEMO	210	mg	3	287	338	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1738	CHEMO	191.4	mg	29	422	658	null	Toptecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1738	CHEMO	6200	mg/m2	6	709	843	null	Gemzar	RECURRENCE	null	
TCGA-61-1740	HORMONAL	1020	mg	null	23	74	null	Tamoxifen	ADJUVANT	null	
TCGA-61-1741	CHEMO	3799	mg	8	12	179	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1741	CHEMO	2240	mg	8	12	179	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1741	CHEMO	838	mg	3	521	604	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1741	CHEMO	1750	mg	3	521	604	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1741	HORMONAL	null	null	null	null	null	null	Tamoxifen	RECURRENCE	ORAL	
TCGA-61-1743	CHEMO	null	null	6	40	172	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1743	CHEMO	null	null	6	40	172	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1895	CHEMO	3780	mg	6	43	155	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1895	CHEMO	400	mg	6	43	155	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1899	CHEMO	2220	mg	6	52	159	null	Carbplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1899	CHEMO	1104	mg	6	52	159	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1900	CHEMO	250	mg	2	null	76	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1900	CHEMO	135	mg	null	35	76	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1900	CHEMO	75	mg	2	35	76	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1901	CHEMO	2098	mg	8	28	294	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1901	CHEMO	3941	mg	8	28	294	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1903	CHEMO	null	mg	6	32	147	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1903	CHEMO	null	mg	6	32	147	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1903	CHEMO	null	mg	6	32	147	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1904	CHEMO	720	mg	5	42	161	null	Taxotere	ADJUVANT	IV AND IP	
TCGA-61-1904	CHEMO	2600	mg	5	42	161	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1906	CHEMO	6	AUC	6	27	153	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	2076	mg	6	27	153	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	7.8	mg	2	279	321	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	234	mg	3	335	391	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	1600	mg	4	400	484	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	1000	mg	4	400	484	null	Avastin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	1500	mg	10	489	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1906	CHEMO	5	AUC	10	489	1038	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1907	CHEMO	768	mg	6	37	163	null	Oxaliplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1907	CHEMO	678	mg	6	37	163	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1907	CHEMO	14280	mg	17	37	357	null	Avastin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1907	CHEMO	null	null	6	774	927	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1910	CHEMO	4550	mg	6	55	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1910	CHEMO	null	mg	6	55	160	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	4650	mg	6	34	143	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	1710	mg	6	34	143	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	8400	mg	6	892	997	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	3000	mg	6	892	997	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	9800	mg	null	1305	1432	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	500	mg	7	1305	1432	null	Avastin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1911	CHEMO	5700	mg	7	1305	1432	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1913	CHEMO	720	mg	6	21	127	null	Docetaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1913	CHEMO	3930	mg	6	21	127	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1914	CHEMO	2400	mg	8	22	192	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1914	CHEMO	3360	mg	8	22	192	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1914	CHEMO	1890	mg	6	1752	1871	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1914	CHEMO	2580	mg	6	1752	1871	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-1914	HORMONAL	1030	mg	null	1155	1672	null	Tamoxifen	ADJUVANT	null	
TCGA-61-1915	CHEMO	1560	mg	6	25	-223	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1915	CHEMO	3300	mg	6	25	143	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1917	CHEMO	null	null	null	19	null	null	Gemzar	ADJUVANT	null	
TCGA-61-1917	CHEMO	null	null	null	19	null	null	Carboplatin	ADJUVANT	null	
TCGA-61-1917	CHEMO	null	null	null	19	null	null	Taxol	ADJUVANT	null	
TCGA-61-1918	CHEMO	4686	mg	6	-25	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1918	CHEMO	2179	mg	6	-25	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1918	CHEMO	15616	mg	6	-25	null	null	Gemcitibine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1919	null	null	null	null	null	null	null	null	null	null	
TCGA-61-1995	CHEMO	3202	mg	4	66	131	null	Cisplatin	ADJUVANT	IV AND IP	
TCGA-61-1995	CHEMO	1311	mg	4	66	131	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-1998	CHEMO	188	mg	2	10	77	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1998	CHEMO	6	AUC	6	52	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-1998	CHEMO	175	mg/m2	6	52	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2000	CHEMO	1905	mg	3	28	231	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-61-2000	CHEMO	2130	mg	9	28	231	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-2000	CHEMO	720	mg	6	28	231	null	CCDP	ADJUVANT	IV AND IP	
TCGA-61-2000	CHEMO	390	mg	6	28	231	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-2000	CHEMO	508	mg	4	420	491	null	Docetaxel	RECURRENCE	IV AND IP	
TCGA-61-2000	CHEMO	367	mg	4	420	491	null	Oxaliplatin	RECURRENCE	IV AND IP	
TCGA-61-2000	CHEMO	3780	mg	4	525	588	null	Avastin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2000	CHEMO	855	mg	9	525	588	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2002	CHEMO	1668	mg	6	24	129	null	Paclitaxel	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2002	CHEMO	4800	mg	6	24	129	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2002	CHEMO	924	mg	14	157	563	null	Doxorubicin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-61-2002	CHEMO	6600	mg	10	400	558	null	Avastin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-61-2003	CHEMO	null	null	null	52	120	null	Carboplatin	ADJUVANT	IV AND IP	
TCGA-61-2003	CHEMO	null	null	null	52	120	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-2003	CHEMO	null	null	null	52	120	null	Taxol	ADJUVANT	IV AND IP	
TCGA-61-2003	CHEMO	null	null	null	115	null	null	Gemcitabine	PROGRESSION	null	
TCGA-61-2003	CHEMO	null	null	null	121	null	null	Carboplatin	PROGRESSION	null	
TCGA-61-2008	CHEMO	3600	mg	6	29	148	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2008	CHEMO	690	mg	6	29	148	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2008	CHEMO	1260	mg	6	860	978	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2008	CHEMO	702	mg	6	860	978	null	Cisplatin	RECURRENCE	IV AND IP	
TCGA-61-2008	CHEMO	372	mg	6	860	978	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	778	mg	6	41	83	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2009	CHEMO	1545	mg	6	41	83	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2009	CHEMO	1200	mg	7	120	295	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	635	mg	7	120	287	null	Cisplatin	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	490	mg	7	120	295	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	987	mg	7	839	1003	null	Oxaliplatin	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	658	mg	7	839	1003	null	Docetaxel	RECURRENCE	IV AND IP	
TCGA-61-2009	CHEMO	304	mg	4	1100	1126	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2009	HORMONAL	null	null	null	669	null	null	Tomaxifen	RECURRENCE	null	
TCGA-61-2012	CHEMO	null	null	null	29	null	null	Carboplatin	ADJUVANT	null	
TCGA-61-2012	CHEMO	null	null	null	29	null	null	Taxol	ADJUVANT	null	
TCGA-61-2016	null	null	null	null	null	null	null	null	null	null	
TCGA-61-2017	CHEMO	null	null	6	34	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2017	CHEMO	null	null	6	34	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2017	CHEMO	618	mg	6	1053	1186	null	Cisplatin	RECURRENCE	IV AND IP	
TCGA-61-2017	CHEMO	456	mg	6	1053	1186	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2017	CHEMO	1206	mg	6	1053	1186	null	Taxol	RECURRENCE	IV AND IP	
TCGA-61-2018	CHEMO	2010	mg	3	18	59	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2018	CHEMO	639	mg	3	18	59	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2018	CHEMO	460	mg	4	60	138	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2018	CHEMO	1920	mg	4	60	138	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2087	CHEMO	null	null	null	1	null	null	Cisplatin	ADJUVANT	null	
TCGA-61-2087	CHEMO	null	null	null	29	null	null	Taxol	ADJUVANT	null	
TCGA-61-2087	CHEMO	null	null	null	29	null	null	Carboplatin	ADJUVANT	null	
TCGA-61-2088	CHEMO	3900	mg	null	96	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2088	CHEMO	900	mg	null	96	145	null	Taxotere	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2092	CHEMO	null	null	6	41	160	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2092	CHEMO	null	null	6	41	160	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2094	CHEMO	null	null	6	24	166	null	Taxol	ADJUVANT	null	
TCGA-61-2094	CHEMO	null	null	6	24	166	null	Carboplatin	ADJUVANT	null	
TCGA-61-2095	CHEMO	null	null	6	61	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2095	CHEMO	null	null	6	61	602	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2095	CHEMO	null	null	12	783	1188	null	Doxil	RECURRENCE	null	
TCGA-61-2095	CHEMO	null	null	null	1193	1264	null	Topotecan	RECURRENCE	null	
TCGA-61-2095	CHEMO	468	mg	null	1360	1389	null	Oxaliplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2095	CHEMO	null	null	null	1474	null	null	Gemzar	RECURRENCE	null	
TCGA-61-2095	IMMUNO	12	mg	null	210	447	null	Ovarex MA6 B43.13	ADJUVANT	null	
TCGA-61-2096	CHEMO	1440	mg	3	29	79	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	645	mg	3	29	79	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	2200	mg	4	474	544	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	1296	mg	4	474	544	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	1230	mg	3	916	988	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	1876	mg	5	1075	1156	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	9450	mg	6	1191	1372	null	Gemcitabine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	1430	mg	6	1191	1372	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	43.2	mg	4	1723	2010	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2096	CHEMO	5320	mg	4	1723	2010	null	Avastin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2097	CHEMO	3060	mg	6	48	166	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2097	CHEMO	1814	mg	6	48	166	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2097	IMMUNO	null	null	null	48	null	null	Interferon gamma	ADJUVANT	null	
TCGA-61-2098	CHEMO	null	null	6	14	145	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2098	CHEMO	null	null	5	null	145	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2101	CHEMO	1800	mg	6	2	117	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2101	CHEMO	762	mg	6	2	117	null	Cisplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2101	CHEMO	1200	mg	4	152	221	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2101	CHEMO	3050	mg	4	152	221	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2101	CHEMO	1420	mg	null	733	null	null	Gemcitabine	PROGRESSION	null	
TCGA-61-2101	CHEMO	800	mg	null	733	null	null	Hexalin	PROGRESSION	null	
TCGA-61-2101	CHEMO	null	null	null	1103	null	null	Doxil	PROGRESSION	null	
TCGA-61-2101	CHEMO	null	null	null	1157	null	null	Hexalen	PROGRESSION	null	
TCGA-61-2101	CHEMO	null	null	null	1188	null	null	Gemzar	PROGRESSION	null	
TCGA-61-2101	CHEMO	null	null	null	1218	null	null	Doxil	PROGRESSION	null	
TCGA-61-2101	CHEMO	null	null	null	1249	null	null	VP 16	PROGRESSION	null	
TCGA-61-2101	IMMUNO	300	mg/kg	null	1129	null	null	IL 12	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-61-2102	CHEMO	null	null	null	14	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2102	CHEMO	null	null	null	14	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2104	CHEMO	null	null	null	5	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2104	CHEMO	null	null	6	5	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2104	CHEMO	null	null	null	1196	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2104	CHEMO	null	null	null	1196	null	null	Taxol	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2104	CHEMO	200	mg	null	1680	null	null	Cisplatin	RECURRENCE	INTRA-PERITONEAL (IP)	
TCGA-61-2104	CHEMO	null	null	null	null	2337	null	Taxane	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2109	CHEMO	3125	mg	10	14	253	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2109	CHEMO	8910	mg	10	14	253	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2109	CHEMO	9060	mg	5	486	601	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2109	CHEMO	325	mg	5	486	601	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	2970	mg	6	20	161	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	1620	mg	6	20	161	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	28	mg	5	661	770	null	Topotecan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	3900	mg	6	774	930	null	Carbplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	315	mg	5	979	1089	null	Doxil	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2110	CHEMO	12640	mg	5	1089	1239	null	Gemzar	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2110	HORMONAL	null	mg	null	459	null	null	Tamoxifen	PROGRESSION	ORAL	
TCGA-61-2110	IMMUNO	16	null	null	244	356	null	IL 2	PROGRESSION	INTRA-PERITONEAL (IP)	
TCGA-61-2111	CHEMO	3400	mg	null	null	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2111	CHEMO	1500	mg	null	null	null	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2111	CHEMO	null	null	6	null	null	null	Carboplatin	RECURRENCE	null	
TCGA-61-2111	CHEMO	null	null	6	null	null	null	Taxol	RECURRENCE	null	
TCGA-61-2111	CHEMO	512	mg	4	null	null	null	Cisplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2111	CHEMO	4000	mg	4	null	null	null	Cytoxan	RECURRENCE	INTRAVENOUS (IV)	
TCGA-61-2111	CHEMO	null	mg/day	null	null	null	null	Cytoxan	RECURRENCE	null	
TCGA-61-2111	CHEMO	null	mg/m2/week	null	null	null	null	Avastin	RECURRENCE	null	
TCGA-61-2111	HORMONAL	null	null	null	null	null	null	Megace	ADJUVANT	null	
TCGA-61-2111	HORMONAL	null	null	null	null	null	null	Provera	RECURRENCE	null	
TCGA-61-2113	CHEMO	1480	null	6	49	143	null	Taxol	ADJUVANT	INTRAVENOUS (IV)	
TCGA-61-2113	CHEMO	4026	mg	6	49	143	null	Carboplatin	ADJUVANT	null	
TCGA-61-2113	CHEMO	418	null	2	336	392	null	Doxil	ADJUVANT	IV AND IP	
